https://www.immunetolerance.org https://www.immunetolerance.org/search https://www.immunetolerance.org/about-us/news https://www.immunetolerance.org/about-us/about-us https://www.immunetolerance.org/about-us/mission-values https://www.immunetolerance.org/about-us/careers https://www.immunetolerance.org/about-us/partnerships https://www.immunetolerance.org/about-us/support https://www.immunetolerance.org/about-us/achievements https://www.immunetolerance.org/about-us/leadership https://www.immunetolerance.org/for-researchers/lab-protocols https://www.immunetolerance.org/for-researchers/clinical-trials https://www.immunetolerance.org/for-researchers/immune-tolerance-in-allergy-asthma https://www.immunetolerance.org/for-researchers/immune-tolerance-in-autoimmune-disease https://www.immunetolerance.org/for-researchers/immune-tolerance-in-transplantation https://www.immunetolerance.org/for-researchers/immune-tolerance-in-type-1-diabetes https://www.immunetolerance.org/member-portal https://www.immunetolerance.org/for-researchers/core-facilities https://www.immunetolerance.org/for-researchers/policies https://www.immunetolerance.org/for-researchers/publications-policy https://www.immunetolerance.org/for-researchers/proposals https://www.immunetolerance.org/for-researchers/submit-proposal https://www.immunetolerance.org/for-researchers/current-rfps https://www.immunetolerance.org/for-researchers/past-rfps https://www.immunetolerance.org/for-researchers/trialshare https://www.immunetolerance.org/for-researchers/strategic-plans https://www.immunetolerance.org/for-researchers/strategic-plan-allergy https://www.immunetolerance.org/for-researchers/strategic-plan-autoimmune-disease https://www.immunetolerance.org/for-researchers/strategic-plan-type-1-diabetes https://www.immunetolerance.org/for-researchers/strategic-plan-transplantation https://www.immunetolerance.org/for-researchers/publications https://www.immunetolerance.org/for-patients/clinical-trials https://www.immunetolerance.org/for-patients/immune-tolerance-in-allergy-asthma https://www.immunetolerance.org/for-patients/immune-tolerance-in-autoimmune-disease https://www.immunetolerance.org/for-patients/immune-tolerance-in-transplantation https://www.immunetolerance.org/for-patients/currently-enrolling-trials-in-kidney-transplantation https://www.immunetolerance.org/for-patients/currently-enrolling-trials-in-liver-transplantation https://www.immunetolerance.org/for-patients/immune-tolerance-in-type-1-diabetes https://www.immunetolerance.org/for-patients/clinical-trials-info https://www.immunetolerance.org/contact/contact https://www.immunetolerance.org/contact/benaroya-research-institute---seattle-office https://www.immunetolerance.org/contact/university-of-california-san-francisco---san-francisco-office https://www.immunetolerance.org/contact/media-inquiries https://www.immunetolerance.org/privacy-policy https://www.immunetolerance.org/terms-of-use https://www.immunetolerance.org/accessibility-statement https://www.immunetolerance.org/search-help https://www.immunetolerance.org/about-us/leadership/philip-bernstein https://www.immunetolerance.org/member-portal/home https://www.immunetolerance.org/member-portal/itn-latest-member-news https://www.immunetolerance.org/member-portal/members/member-information https://www.immunetolerance.org/member-portal/members/nec-members https://www.immunetolerance.org/member-portal/members/nsc-members https://www.immunetolerance.org/member-portal/members/allergy-asthma-assessment-group https://www.immunetolerance.org/member-portal/members/autoimmune-disease-assessment-group https://www.immunetolerance.org/member-portal/members/transplantation-assessment-group https://www.immunetolerance.org/member-portal/members/type-1-diabetes-assessment-group https://www.immunetolerance.org/member-portal/contacts https://www.immunetolerance.org/member-portal/studies https://www.immunetolerance.org/member-portal/library/videos https://www.immunetolerance.org/member-portal/library/library https://www.immunetolerance.org/member-portal/library/itn-acronyms https://www.immunetolerance.org/member-portal/it-support https://www.immunetolerance.org/member-portal/it-system-status-automated https://www.immunetolerance.org/for-researchers/publications-citations https://www.immunetolerance.org/about-us/leadership/dawn-smilek https://www.immunetolerance.org/about-us/leadership/mark-anderson https://www.immunetolerance.org/about-us/leadership/bill-st-clair https://www.immunetolerance.org/about-us/leadership/christian-larsen https://www.immunetolerance.org/about-us/leadership/david-fox https://www.immunetolerance.org/about-us/leadership/tanya-laidlaw https://www.immunetolerance.org/about-us/leadership/mary-roy https://www.immunetolerance.org/about-us/leadership/jerry-nepom https://www.immunetolerance.org/news-immunetolerance-org/18-month-data-from-rave-trial-to-be-reported-this-week-at-acr https://www.immunetolerance.org/news-immunetolerance-org/2012-annual-technical-report-deadline-approaching https://www.immunetolerance.org/news-immunetolerance-org/2012-kick-off https://www.immunetolerance.org/news-immunetolerance-org/2012-performance-evaluations-now-available https://www.immunetolerance.org/news-immunetolerance-org/2013-employee-evaluations-now-available https://www.immunetolerance.org/news-immunetolerance-org/2016-year-end-summary https://www.immunetolerance.org/news-immunetolerance-org/a-potential-test-tube-assay-for-food-allergy https://www.immunetolerance.org/news-immunetolerance-org/a-strong-association-between-malt1-locus-and-peanut-allergy https://www.immunetolerance.org/news-immunetolerance-org/a-transplant-breakthrough-by-itn-investigators https://www.immunetolerance.org/news-immunetolerance-org/a-view-towards-immune-tolerance---a-five-part-series https://www.immunetolerance.org/news-immunetolerance-org/a-view-towards-immune-tolerance---part-2 https://www.immunetolerance.org/news-immunetolerance-org/a-view-towards-immune-tolerance---part-3 https://www.immunetolerance.org/news-immunetolerance-org/a-view-towards-immune-tolerance---part-4 https://www.immunetolerance.org/news-immunetolerance-org/a-view-towards-immune-tolerance---part-5 https://www.immunetolerance.org/news-immunetolerance-org/aaron-gannon---december-2011-achiever-award-winner https://www.immunetolerance.org/news-immunetolerance-org/aaron-gannon-promoted-to-director-of-it-operations https://www.immunetolerance.org/news-immunetolerance-org/abatacept-for-lupus-nephritis-the-access-study https://www.immunetolerance.org/news-immunetolerance-org/abatacept-in-relapsing-remitting-multiple-sclerosis https://www.immunetolerance.org/news-immunetolerance-org/acceptor-kidney-transplant-study-opens-for-enrollment https://www.immunetolerance.org/news-immunetolerance-org/access-lupus-nephritis-study-completes-enrollment-early https://www.immunetolerance.org/news-immunetolerance-org/achiever-award-for-q3-michael-konieczny https://www.immunetolerance.org/news-immunetolerance-org/activate-study-investigating-microbiome-exposure-in-c-section-infants-and-allergy-development-begins-recruitment https://www.immunetolerance.org/news-immunetolerance-org/agenda-for-april-2015-itn-nsc-meeting https://www.immunetolerance.org/news-immunetolerance-org/alefacept-preserves-beta-cell-function-in-some-new-onset-type-1-diabetes-patients-out-to-two-years https://www.immunetolerance.org/news-immunetolerance-org/allergy-asthma-and-covid-19-susceptibility https://www.immunetolerance.org/news-immunetolerance-org/american-academy-of-pediatrics-endorses-early-peanut-introduction-based-on-itns-leap-study https://www.immunetolerance.org/news-immunetolerance-org/american-diabetes-associations-71st-scientific-sessions https://www.immunetolerance.org/news-immunetolerance-org/an-update-on-tolerant-kidney-transplant-recipients https://www.immunetolerance.org/news-immunetolerance-org/announcing-the-itn-member-portal https://www.immunetolerance.org/news-immunetolerance-org/antithymocyte-globulin-in-type-1-diabetes-two-year-results-from-the-start-study https://www.immunetolerance.org/news-immunetolerance-org/april-2012-nsc-meeting-summary https://www.immunetolerance.org/news-immunetolerance-org/april-2013-network-steering-committee-meeting-recap https://www.immunetolerance.org/news-immunetolerance-org/august-17-deadline-for-allergy-and-asthma-concept-proposals https://www.immunetolerance.org/news-immunetolerance-org/bar-or-wins-2025-dystel-prize---national-ms-society https://www.immunetolerance.org/news-immunetolerance-org/bdr-is-the-new-department-name-for-tada-trpmo https://www.immunetolerance.org/news-immunetolerance-org/bdr-mechanistic-operations-announcement https://www.immunetolerance.org/news-immunetolerance-org/bdr-priorities-and-deadlines-announced https://www.immunetolerance.org/news-immunetolerance-org/bdr-welcomes-kidan-kebede https://www.immunetolerance.org/news-immunetolerance-org/beat-ms-a-clinical-trial-of-autologous-hematopoietic-stem-cell-transplantation-versus-best-available-therapy-for-multiple-sclerosis-begins-enrollment https://www.immunetolerance.org/news-immunetolerance-org/benaroya-research-institutes-jerry-nepom-named-immune-tolerance-network-director https://www.immunetolerance.org/news-immunetolerance-org/best-wishes-lily https://www.immunetolerance.org/news-immunetolerance-org/bioshare---biomarker-sample-sharing-opportunity-launched-november-1-2010 https://www.immunetolerance.org/news-immunetolerance-org/bravos-study-for-scleroderma-begins-recruitment https://www.immunetolerance.org/news-immunetolerance-org/calibrate-trial-for-lupus-nephritis-opens https://www.immunetolerance.org/news-immunetolerance-org/call-for-proposals-clinical-trials-of-psoriasis-and-autoimmune-dermatological-disorders https://www.immunetolerance.org/news-immunetolerance-org/celebrate-ten-years-of-tolerance https://www.immunetolerance.org/news-immunetolerance-org/chris-larsen-awarded-the-pioneer-award-at-wtc-2025 https://www.immunetolerance.org/news-immunetolerance-org/compilation-of-2011-annual-technical-report-to-begin https://www.immunetolerance.org/news-immunetolerance-org/congratulations-juliete-a-f-silva-ms-phd https://www.immunetolerance.org/news-immunetolerance-org/ctg-welcomes-aboard-luke-lee https://www.immunetolerance.org/news-immunetolerance-org/ctg-welcomes-sabrina-hurley-by-way-of-bethesda https://www.immunetolerance.org/news-immunetolerance-org/data-from-itn-lupus-nephritis-study-to-be-presented-at-upcoming-rheumatology-and-nephrology-conferences https://www.immunetolerance.org/news-immunetolerance-org/data-from-itn-rave-study-to-be-presented-at-american-college-of-rheumatology-meeting https://www.immunetolerance.org/news-immunetolerance-org/december-update-funding-renewal-faqs https://www.immunetolerance.org/news-immunetolerance-org/docushare-shut-down https://www.immunetolerance.org/news-immunetolerance-org/dr-jerry-nepom-receives-2017-george-eisenbarth-award https://www.immunetolerance.org/news-immunetolerance-org/dr-kristina-harris-has-newly-joined-bdr https://www.immunetolerance.org/news-immunetolerance-org/drs-nepom-and-corren-discuss-the-catnip-study-with-radio-pet-lady-tracie-hotchner https://www.immunetolerance.org/news-immunetolerance-org/durable-hay-fever-suppression-may-require-three-years-of-immunotherapy https://www.immunetolerance.org/news-immunetolerance-org/early-consumption-of-peanuts-prevents-peanut-allergy-in-high-risk-infants https://www.immunetolerance.org/news-immunetolerance-org/expert-panel-on-food-allergies https://www.immunetolerance.org/news-immunetolerance-org/extend-study-video-now-available https://www.immunetolerance.org/news-immunetolerance-org/extension-of-the-pediatric-liver-transplantation-trial-is-planned-for-immunosuppression-withdrawn-participants-reaching-the-end-of-the-two-year-observation-period https://www.immunetolerance.org/news-immunetolerance-org/fall-2011-nsc-meeting-highlights https://www.immunetolerance.org/news-immunetolerance-org/fall-2014-itn-network-steering-committee-nsc-meeting-dates https://www.immunetolerance.org/news-immunetolerance-org/fall-2015-network-steering-committee-meeting-october-13-14-2015 https://www.immunetolerance.org/news-immunetolerance-org/farewell-to-jenice-dcosta https://www.immunetolerance.org/news-immunetolerance-org/farewell-to-sachin-malhotra https://www.immunetolerance.org/news-immunetolerance-org/farewell-to-winnie-felix https://www.immunetolerance.org/news-immunetolerance-org/fda-panel https://www.immunetolerance.org/news-immunetolerance-org/first-beat-ms-participant-has-been-enrolled-and-randomized https://www.immunetolerance.org/news-immunetolerance-org/first-patient-transplanted-in-the-acceptor-study https://www.immunetolerance.org/news-immunetolerance-org/first-subject-transplanted-in-expanded-study-of-mixed-chimerism-in-kidney-transplantation https://www.immunetolerance.org/news-immunetolerance-org/five-year-follow-up-of-wisp-r-pediatric-liver-transplant-recipients https://www.immunetolerance.org/news-immunetolerance-org/fond-farewell-to-carol-genseal https://www.immunetolerance.org/news-immunetolerance-org/gideon-one-of-time100-most-influential-people-in-health https://www.immunetolerance.org/news-immunetolerance-org/goodbye-and-best-wishes-to-stephanie-chan https://www.immunetolerance.org/news-immunetolerance-org/goodbye-and-good-luck-michele-cherian https://www.immunetolerance.org/news-immunetolerance-org/grass-durham-study-of-grass-pollen-allergy-in-uk-enters-enrollment-phase https://www.immunetolerance.org/news-immunetolerance-org/grass-hay-fever-study-completes-enrollment-early https://www.immunetolerance.org/news-immunetolerance-org/grass-mechanistic-manuscript-highlighted-as-jaci-editors-choice https://www.immunetolerance.org/news-immunetolerance-org/halt-ms-data-to-be-presented-at-the-american-society-of-hematology-annual-meeting https://www.immunetolerance.org/news-immunetolerance-org/halt-ms-therapy-effective-for-inducing-long-term-sustained-remission-of-ms-through-5-years-after-transplant https://www.immunetolerance.org/news-immunetolerance-org/immune-tolerance-networks-itn-trialshare-wins-national-academies-board-on-research-data-and-information-challenge https://www.immunetolerance.org/news-immunetolerance-org/immunotherapy-research-in-seattle-and-the-itn https://www.immunetolerance.org/news-immunetolerance-org/impact-study-for-peanut-allergy-completes-enrollment https://www.immunetolerance.org/news-immunetolerance-org/impact-study-launches-today-peanut-oral-immunotherapy-in-young-children https://www.immunetolerance.org/news-immunetolerance-org/in-memory-of-george-eisenbarth-md https://www.immunetolerance.org/news-immunetolerance-org/introducing-new-bdr-senior-director-michael-howell-phd https://www.immunetolerance.org/news-immunetolerance-org/itn-achieves-scientific-manuscript-first---provides-open-interactive-access-to-clinical-trial-data-with-new-publication-rituximab-therapy-effective-for-anca-associated-vasculitis https://www.immunetolerance.org/news-immunetolerance-org/itn-allergy-data-to-be-presented-at-eaaci https://www.immunetolerance.org/news-immunetolerance-org/itn-allergy-mechanistic-data-at-aaaai-annual-meeting https://www.immunetolerance.org/news-immunetolerance-org/itn-and-bri-exchange-federation https://www.immunetolerance.org/news-immunetolerance-org/itn-announces-enrollment-of-first-participant-in-t1dal-trial-for-people-recently-diagnosed-with-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/itn-announces-enrollment-of-first-patient-in-part-i-of-the-retain-trial-for-newly-diagnosed-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/itn-announces-enrollment-of-first-patient-in-phase-ii-trial-for-relapsing-remitting-multiple-sclerosis https://www.immunetolerance.org/news-immunetolerance-org/itn-bioinformatics-group-wins-partners-in-excellence-award https://www.immunetolerance.org/news-immunetolerance-org/itn-completes-enrollment-in-pediatric-liver-transplantation-study https://www.immunetolerance.org/news-immunetolerance-org/itn-completes-enrollment-of-abate-trial-of-teplizumab-in-new-onset-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/itn-director-bluestone-appointed-executive-vice-chancellor-and-provost-at-ucsf https://www.immunetolerance.org/news-immunetolerance-org/itn-hayfever-pilot-study-data-to-be-presented-at-world-allergy-congress https://www.immunetolerance.org/news-immunetolerance-org/itn-helped-support-mechanistic-studies-in-new-t1d-immunotherapy-publication https://www.immunetolerance.org/news-immunetolerance-org/itn-hosts-a-view-towards-immune-tolerance-symposium-at-focis-2012 https://www.immunetolerance.org/news-immunetolerance-org/itn-job-posting-director-of-biomarker-discovery-research https://www.immunetolerance.org/news-immunetolerance-org/itn-launches-the-catnip-cat-allergy-immunotherapy-study https://www.immunetolerance.org/news-immunetolerance-org/itn-launches-the-pause-study-in-psoriasis https://www.immunetolerance.org/news-immunetolerance-org/itn-leap-trial-cited-in-new-york-times-report-about-the-drop-in-peanut-allergy https://www.immunetolerance.org/news-immunetolerance-org/itn-mentioned-in-article-about-immunotherapy-research-in-seattle https://www.immunetolerance.org/news-immunetolerance-org/itn-mourns-the-passing-of-lloyd-mayer https://www.immunetolerance.org/news-immunetolerance-org/itn-multiple-sclerosis-trial-data-to-be-presented-at-american-society-of-hematology-annual-meeting https://www.immunetolerance.org/news-immunetolerance-org/itn-network-director-mark-anderson-receives-william-b-coley-award https://www.immunetolerance.org/news-immunetolerance-org/itn-opens-alltol-study-for-organ-transplant-recipients https://www.immunetolerance.org/news-immunetolerance-org/itn-opens-anca-associated-vasculitis-biomarker-study-in-the-uk https://www.immunetolerance.org/news-immunetolerance-org/itn-opens-pilot-study-to-compare-allergen-challenge-methods-cat-eec-study https://www.immunetolerance.org/news-immunetolerance-org/itn-opens-the-extend-study-in-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/itn-opens-the-optimal-study-for-liver-transplant-recipients https://www.immunetolerance.org/news-immunetolerance-org/itn-peanut-allergy-prevention-study-highlighted-in-the-wall-street-journal https://www.immunetolerance.org/news-immunetolerance-org/itn-research-forum-presentation-videos-available-in-member-portal-library https://www.immunetolerance.org/news-immunetolerance-org/itn-scheduler https://www.immunetolerance.org/news-immunetolerance-org/itn-study-published-in-jama-shows-successful-immunosuppression-weaning-in-pediatric-liver-recipients https://www.immunetolerance.org/news-immunetolerance-org/itn-transplant-data-at-american-transplant-congress-2012 https://www.immunetolerance.org/news-immunetolerance-org/itn-transplant-data-to-be-presented-at-american-transplant-congress-atc-meeting-in-seattle-wa https://www.immunetolerance.org/news-immunetolerance-org/itn-trialshare-absorbs-bioshare https://www.immunetolerance.org/news-immunetolerance-org/itn-trialshare-is-highlighted-as-top-story-in-clinical-informatics-news https://www.immunetolerance.org/news-immunetolerance-org/itn-trialshare-sees-public-usage-rise-following-publication-of-the-first-manuscript-with-embedded-links-to-the-system https://www.immunetolerance.org/news-immunetolerance-org/itn-type-1-diabetes-data-to-be-featured-at-the-american-diabetes-association-ada-scientific-sessions https://www.immunetolerance.org/news-immunetolerance-org/itn-type-1-diabetes-roundup-at-the-international-diabetes-federation-idf-and-immunology-of-diabetes-society-ids-meetings https://www.immunetolerance.org/news-immunetolerance-org/itn-vitiligo-clinical-trial-in-the-news https://www.immunetolerance.org/news-immunetolerance-org/itn-vitiligo-clinical-trial-reveal-in-the-news https://www.immunetolerance.org/news-immunetolerance-org/itn-will-receive-national-academies-award-for-trialshare-on-october-23rd https://www.immunetolerance.org/news-immunetolerance-org/itn-wins-nih-award-for-collaborative-network-for-tolerance-research https://www.immunetolerance.org/news-immunetolerance-org/itn-year-in-review https://www.immunetolerance.org/news-immunetolerance-org/itn034ai-access-trial-enrollment-n-100 https://www.immunetolerance.org/news-immunetolerance-org/itns-access-trial-for-lupus-nephritis-enrolls-first-patient https://www.immunetolerance.org/news-immunetolerance-org/itns-cateec-article-selected-as-editors-choice-feature-by-jaci https://www.immunetolerance.org/news-immunetolerance-org/itns-christian-larsen-m-d-d-phil-presented-with-ama-scientific-achievement-award https://www.immunetolerance.org/news-immunetolerance-org/itns-christian-larsen-md-dphil-presented-with-ama-scientific-achievement-award https://www.immunetolerance.org/news-immunetolerance-org/itns-leap-and-halt-ms-trials-included-in-niaids-15-selected-research-advances-for-2015 https://www.immunetolerance.org/news-immunetolerance-org/itns-leap-study-continues-to-influence-dietary-guidance-for-infants-as-well-as-product-development https://www.immunetolerance.org/news-immunetolerance-org/itns-leap-study-manuscript-has-been-selected-as-one-of-the-most-notable-articles-of-2015 https://www.immunetolerance.org/news-immunetolerance-org/itns-leap-study-of-peanut-allergy-completes-enrollment-of-640-children https://www.immunetolerance.org/news-immunetolerance-org/itns-leap-study-recognized-by-society-for-clinical-trials https://www.immunetolerance.org/news-immunetolerance-org/itns-reboot-study-for-primary-membranous-nephropathy-has-first-patient-visit https://www.immunetolerance.org/news-immunetolerance-org/itns-start-study-of-newly-diagnosed-type-1-diabetes-begins-pediatric-enrollment https://www.immunetolerance.org/news-immunetolerance-org/itns-trialshare-wins-honorable-mention-at-bio-it-world-best-practices-awards https://www.immunetolerance.org/news-immunetolerance-org/jason-woods-departure https://www.immunetolerance.org/news-immunetolerance-org/job-opening-technical-support-analyst https://www.immunetolerance.org/news-immunetolerance-org/july-itn-directors-f2f-meeting-at-bri-in-seattle-wa https://www.immunetolerance.org/news-immunetolerance-org/just-released-funding-renewal-faqs https://www.immunetolerance.org/news-immunetolerance-org/kidney-graft-function-and-a-b-cell-signature https://www.immunetolerance.org/news-immunetolerance-org/kidney-transplant-tolerance-signatures-published-in-two-separate-jci-reports https://www.immunetolerance.org/news-immunetolerance-org/kidney-transplantation-observation-study-completes-enrollment https://www.immunetolerance.org/news-immunetolerance-org/landmark-study-of-islet-transplantation-reveals-potential-benefits-in-uncontrolled-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/largest-immunosuppression-withdrawal-trial-in-liver-transplant-recipients-undertaken-by-itn-completes-enrollment https://www.immunetolerance.org/news-immunetolerance-org/last-patient-in-greenbaum-il2-rapa-combination-study-completed-primary-endpoint-visit https://www.immunetolerance.org/news-immunetolerance-org/last-patient-last-visit-for-impact-trial https://www.immunetolerance.org/news-immunetolerance-org/latest-results-from-international-islet-transplant-study-confirm-potential-patient-benefits https://www.immunetolerance.org/news-immunetolerance-org/leap-participant-follow-up-study-publication https://www.immunetolerance.org/news-immunetolerance-org/leap-reveal-roundup https://www.immunetolerance.org/news-immunetolerance-org/leap-trio-study---washington-post https://www.immunetolerance.org/news-immunetolerance-org/letter-from-jerry https://www.immunetolerance.org/news-immunetolerance-org/letter-from-jerry-2 https://www.immunetolerance.org/news-immunetolerance-org/letter-from-jerry-3 https://www.immunetolerance.org/news-immunetolerance-org/letter-from-jerry-4 https://www.immunetolerance.org/news-immunetolerance-org/letter-from-jerry-5 https://www.immunetolerance.org/news-immunetolerance-org/letter-from-jerry-6 https://www.immunetolerance.org/news-immunetolerance-org/littmus-clinical-trial-is-open https://www.immunetolerance.org/news-immunetolerance-org/littmus-trial-announces-first-liver-transplant https://www.immunetolerance.org/news-immunetolerance-org/may-itn-network-steering-committee-will-not-meet-in-person https://www.immunetolerance.org/news-immunetolerance-org/may-nsc-meeting-presentation-slides-posted-for-committee-members https://www.immunetolerance.org/news-immunetolerance-org/may-nsc-meeting-presentation-slides-posted-for-committee-members-2 https://www.immunetolerance.org/news-immunetolerance-org/mechanisms-of-tolerance-symposium-at-annual-focis-meeting https://www.immunetolerance.org/news-immunetolerance-org/message-from-dr-larry-turka https://www.immunetolerance.org/news-immunetolerance-org/mitzi-dooley-will-be-leaving-the-itn-july-25-2012 https://www.immunetolerance.org/news-immunetolerance-org/mourning-the-loss-of-dr-josh-levitsky https://www.immunetolerance.org/news-immunetolerance-org/new-5-year-15-million-research-grant-program-to-accelerate-immune-tolerance-therapies-for-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/new-corporate-graphic-standards https://www.immunetolerance.org/news-immunetolerance-org/new-hire-aditya-badhwar https://www.immunetolerance.org/news-immunetolerance-org/new-hire-robert-yates https://www.immunetolerance.org/news-immunetolerance-org/new-hr-operations-analyst https://www.immunetolerance.org/news-immunetolerance-org/new-itn-oral-tolerance-pilot-study-enrolls-first-patients https://www.immunetolerance.org/news-immunetolerance-org/new-itn-powerpoint-templates https://www.immunetolerance.org/news-immunetolerance-org/new-look-and-features-for-itn-public-website https://www.immunetolerance.org/news-immunetolerance-org/new-look-for-the-itn-insiders-report https://www.immunetolerance.org/news-immunetolerance-org/new-member-portal https://www.immunetolerance.org/news-immunetolerance-org/new-online-pre-screener-for-t1dal-study https://www.immunetolerance.org/news-immunetolerance-org/new-peanut-allergy-prevention-guidelines-released-based-on-itns-leap-study-results https://www.immunetolerance.org/news-immunetolerance-org/new-publication-abate-type-1-diabetes-study-reveals-subset-of-patients-with-strong-response-to-therapy https://www.immunetolerance.org/news-immunetolerance-org/new-publication-angiopoeitin-2-in-anca-associated-vasculitis https://www.immunetolerance.org/news-immunetolerance-org/new-publication-approaches-to-establishing-tolerance-in-immune-mediated-diseases https://www.immunetolerance.org/news-immunetolerance-org/new-publication-b-cell-signature-in-tolerant-kidney-transplant-recipients https://www.immunetolerance.org/news-immunetolerance-org/new-publication-biomarker-study-from-the-rave-trial https://www.immunetolerance.org/news-immunetolerance-org/new-publication-clinical-outcomes-of-remission-induction-therapy-for-severe-anca-associated-vasculitis https://www.immunetolerance.org/news-immunetolerance-org/new-publication-differential-induction-of-allergen-specific-iga-responses-following-timothy-grass-subcutaneous-and-sublingual-immunotherapy https://www.immunetolerance.org/news-immunetolerance-org/new-publication-effect-of-costimulatory-blockade-with-abatacept-after-ustekinumab-withdrawal-in-patients-with-moderate-to-severe-plaque-psoriasis https://www.immunetolerance.org/news-immunetolerance-org/new-publication-from-catnip-trial-anti-tslp-plus-antigen-specific-immunotherapy-for-induction-of-tolerance-in-individuals-with-cat-allergy https://www.immunetolerance.org/news-immunetolerance-org/new-publication-from-extend-trial-il-6-receptor-blockade-does-not-slow-v-cell-loss-in-new-onset-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/new-publication-from-impact-trial-efficacy-and-safety-of-oral-immunotherapy-in-children-aged-1-3-years-with-peanut-allergy https://www.immunetolerance.org/news-immunetolerance-org/new-publication-grass-pollen-nasal-allergen-challenge-for-assessing-outcomes https://www.immunetolerance.org/news-immunetolerance-org/new-publication-high-throughput-gene-sequencing-to-estimate-t-cell-populations https://www.immunetolerance.org/news-immunetolerance-org/new-publication-il-2-and-rapamycin-in-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/new-publication-indirect-pathway-t-cell-responses-reflect-outcomes-in-kidney-transplant-recipients https://www.immunetolerance.org/news-immunetolerance-org/new-publication-itn-rave-study-effective-paradigm-for-trials-in-orphan-diseases https://www.immunetolerance.org/news-immunetolerance-org/new-publication-itns-type-1-diabetes-preclinical-consortiums-first-combination-therapy-study https://www.immunetolerance.org/news-immunetolerance-org/new-publication-long-term-follow-up-of-islet-transplant-protocol https://www.immunetolerance.org/news-immunetolerance-org/new-publication-partial-exhaustion-of-cd8-t-cells-in-responders-to-anti-cd3-treatment-in-new-onset-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/new-publication-predictors-of-peanut-sensitization-to-identify-infants-at-high-risk-for-peanut-allergy https://www.immunetolerance.org/news-immunetolerance-org/new-publication-results-from-the-t1dal-type-1-diabetes-study https://www.immunetolerance.org/news-immunetolerance-org/new-publication-start-type-1-diabetes-study-showed-no-difference-in-insulin-production-decline https://www.immunetolerance.org/news-immunetolerance-org/new-publication-statins-in-multiple-sclerosis https://www.immunetolerance.org/news-immunetolerance-org/new-publication-t-cell-reconstitution-following-autologous-stem-cell-transplant-in-patients-with-multiple-sclerosis https://www.immunetolerance.org/news-immunetolerance-org/new-publication-uncovering-pathways-to-personalized-therapies-in-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/new-review-lymphodepletion-and-homeostatic-proliferation-in-transplantation https://www.immunetolerance.org/news-immunetolerance-org/new-rfp---clinical-trials-of-allogeneic-solid-organ-transplantation-plus-therapeutic-cell-transfer https://www.immunetolerance.org/news-immunetolerance-org/new-trialshare-hotline https://www.immunetolerance.org/news-immunetolerance-org/new-white-paper---tolerance-one-transplant-for-life https://www.immunetolerance.org/news-immunetolerance-org/niaid-launches-online-database-for-global-clinical-researchers https://www.immunetolerance.org/news-immunetolerance-org/nih-renews-its-dedication-to-fighting-worldwide-asthma https://www.immunetolerance.org/news-immunetolerance-org/note-from-jerry https://www.immunetolerance.org/news-immunetolerance-org/nsc-meeting-presentation-slides-posted-for-committee-members https://www.immunetolerance.org/news-immunetolerance-org/nsc-meeting-updates https://www.immunetolerance.org/news-immunetolerance-org/nutritional-impact-of-peanut-consumption-in-the-leap-study https://www.immunetolerance.org/news-immunetolerance-org/october-2012-nsc-meeting-recap https://www.immunetolerance.org/news-immunetolerance-org/october-2013-nsc-meeting-summary https://www.immunetolerance.org/news-immunetolerance-org/october-2015-nsc-presentations https://www.immunetolerance.org/news-immunetolerance-org/online-pre-screen-questionnaire-is-launched-on-acclaim-ms-website https://www.immunetolerance.org/news-immunetolerance-org/optimal-primary-paper-published https://www.immunetolerance.org/news-immunetolerance-org/optimal-trial-has-completed-enrollment https://www.immunetolerance.org/news-immunetolerance-org/part-ib-of-retain-type-1-diabetes-study-opens-for-enrollment https://www.immunetolerance.org/news-immunetolerance-org/pause-psoriasis-trial-completes-enrollment https://www.immunetolerance.org/news-immunetolerance-org/pause-study-video-now-available https://www.immunetolerance.org/news-immunetolerance-org/peanut-allergy-development https://www.immunetolerance.org/news-immunetolerance-org/pilot-study-seeks-to-understand-biomarkers-in-cat-allergy-response https://www.immunetolerance.org/news-immunetolerance-org/pilot-study-to-compare-nasal-allergen-challenge-with-environmental-chamber-challenges-cateec-completes-enrollment https://www.immunetolerance.org/news-immunetolerance-org/please-welcome-new-bdr-scientist-dr-jenice-dcosta https://www.immunetolerance.org/news-immunetolerance-org/possible-first-new-treatment-for-anca-associated-vasculitis-in-40-years https://www.immunetolerance.org/news-immunetolerance-org/postponed-deadline-for-performance-evaluations https://www.immunetolerance.org/news-immunetolerance-org/predicting-peanut-allergy https://www.immunetolerance.org/news-immunetolerance-org/presentations-from-may-nsc-posted https://www.immunetolerance.org/news-immunetolerance-org/presentations-from-october-2016-network-steering-committee-meeting https://www.immunetolerance.org/news-immunetolerance-org/prophylactic-use-of-sublingual-allergen-immunotherapy-in-high-risk-children https://www.immunetolerance.org/news-immunetolerance-org/protection-against-peanut-allergy-by-early-consumption-persists-following-a-one-year-period-of-peanut-avoidance https://www.immunetolerance.org/news-immunetolerance-org/public-launch-of-itn-trialshare-the-itns-new-clinical-trials-research-portal https://www.immunetolerance.org/news-immunetolerance-org/radio-interview-when-should-children-be-introduced-to-peanut-products https://www.immunetolerance.org/news-immunetolerance-org/rave-study-data-presented-at-16th-international-vasculitis-anca-workshop-in-paris https://www.immunetolerance.org/news-immunetolerance-org/recommendations-of-itn-jdrf-combination-therapy-assessment-group-published https://www.immunetolerance.org/news-immunetolerance-org/reduced-hypoglycemic-events-and-improved-glycemic-variability-is-associated-with-c-peptide-preservation-in-new-onset-type-1-diabetes-patients-in-the-t1dal-study https://www.immunetolerance.org/news-immunetolerance-org/remembering-jean-francois-bach https://www.immunetolerance.org/news-immunetolerance-org/reminder-august-17-deadline-for-allergy-and-asthma-concept-proposals https://www.immunetolerance.org/news-immunetolerance-org/request-for-expressions-of-interest-for-innovative-clinical-trials-in-type-1-diabetes https://www.immunetolerance.org/news-immunetolerance-org/request-for-proposal-mechanistic-assays-on-stored-samples-from-the-grass-trial https://www.immunetolerance.org/news-immunetolerance-org/request-for-proposals---clinical-trials-in-immune-tolerance https://www.immunetolerance.org/news-immunetolerance-org/request-for-proposals-clinical-trials-of-immune-tolerance-for-protein-gene-replacement-therapy https://www.immunetolerance.org/news-immunetolerance-org/request-for-proposals-clinical-trials-of-immune-tolerance-in-solid-organ-transplantation https://www.immunetolerance.org/news-immunetolerance-org/request-for-proposals-clinical-trials-of-immune-tolerance-in-transplantation-using-deceased-donor-organs https://www.immunetolerance.org/news-immunetolerance-org/request-for-proposals-combination-therapy-trials-in-allergy-and-asthma https://www.immunetolerance.org/news-immunetolerance-org/request-for-proposals-itn-seeks-antigen-specific-t-cell-tolerance-assays-for-myelin-associated-antigens-in-multiple-sclerosis https://www.immunetolerance.org/news-immunetolerance-org/restarrt-primary-paper-published https://www.immunetolerance.org/news-immunetolerance-org/restoring-the-balance-immunotherapeutic-combinations-for-autoimmune-disease https://www.immunetolerance.org/news-immunetolerance-org/results-of-itn-insulin-b-chain-study-for-type-1-diabetes-published https://www.immunetolerance.org/news-immunetolerance-org/results-of-itn-mixed-chimerism-study-in-kidney-transplantation-published-in-new-england-journal-of-medicine https://www.immunetolerance.org/news-immunetolerance-org/results-of-itn-phase-i-study-of-ctla4ig-in-multiple-sclerosis-published-in-neurology https://www.immunetolerance.org/news-immunetolerance-org/reveal-study-completes-enrollment https://www.immunetolerance.org/news-immunetolerance-org/secondary-outcomes-in-leap-on-participants https://www.immunetolerance.org/news-immunetolerance-org/seeking-proposals-for-clinical-trials-of-desensitization-in-solid-organ-transplantation https://www.immunetolerance.org/news-immunetolerance-org/specimens-and-funding-for-type-1-diabetes-biomarker-research https://www.immunetolerance.org/news-immunetolerance-org/spring-2014-network-steering-committee-meeting-may-20-21-2014 https://www.immunetolerance.org/news-immunetolerance-org/spring-2014-nsc-meeting-in-seattle https://www.immunetolerance.org/news-immunetolerance-org/start-clinical-trial-press-release-translated-for-inclusion-on-aaas-eurekalert-chinese https://www.immunetolerance.org/news-immunetolerance-org/stem-cell-transplants-may-halt-progression-of-multiple-sclerosis https://www.immunetolerance.org/news-immunetolerance-org/stephen-abreu-will-be-parting-from-the-itn https://www.immunetolerance.org/news-immunetolerance-org/strategic-partnerships-and-business-development-initiative https://www.immunetolerance.org/news-immunetolerance-org/study-shows-six-injection-allergy-vaccine-tames-hay-fever-for-at-least-two-years https://www.immunetolerance.org/news-immunetolerance-org/successful-kick-off-meeting-for-itn055ai-calibrate-study-in-lupus-nephritis https://www.immunetolerance.org/news-immunetolerance-org/t1dal-2-year-clinical-results https://www.immunetolerance.org/news-immunetolerance-org/t1dal-study-completes-enrollment https://www.immunetolerance.org/news-immunetolerance-org/t1dal-study-of-alefacept-in-newly-diagnosed-type-1-diabetes-begins-enrollment-to-younger-ages https://www.immunetolerance.org/news-immunetolerance-org/the-first-activate-baby-has-been-born https://www.immunetolerance.org/news-immunetolerance-org/the-immune-tolerance-network-opens-anca-associated-vasculitis-biomarker-study-in-the-uk https://www.immunetolerance.org/news-immunetolerance-org/the-itn-at-the-american-transplant-congress https://www.immunetolerance.org/news-immunetolerance-org/the-itn-congratulates-the-2025-nobel-prize-in-physiology-or-medicine-winners https://www.immunetolerance.org/news-immunetolerance-org/transplant-rfp-update-itn-invites-two-applications-for-full-review https://www.immunetolerance.org/news-immunetolerance-org/type-1-diabetes-data-to-be-presented-at-european-association-for-the-study-of-diabetes https://www.immunetolerance.org/news-immunetolerance-org/ucsf-members-open-enrollment-announced https://www.immunetolerance.org/news-immunetolerance-org/update-nih-review-of-um1-renewal-application https://www.immunetolerance.org/news-immunetolerance-org/updated-brand-names-guide https://www.immunetolerance.org/news-immunetolerance-org/updated-brand-names-guide-2 https://www.immunetolerance.org/news-immunetolerance-org/updated-brand-names-guide-3 https://www.immunetolerance.org/news-immunetolerance-org/updated-itn-word-and-ppt-templates https://www.immunetolerance.org/news-immunetolerance-org/validated-itn-foxp3-flow-cytometry-methodology-published-graces-cover-of-cytometry-b https://www.immunetolerance.org/news-immunetolerance-org/welcome-aboard-dr-lijing-xu https://www.immunetolerance.org/news-immunetolerance-org/welcome-anitha-achyutha https://www.immunetolerance.org/news-immunetolerance-org/welcome-karen-chia-aparna-shukla-dennis-wightman https://www.immunetolerance.org/news-immunetolerance-org/welcome-sophia-chang-to-nco https://www.immunetolerance.org/news-immunetolerance-org/welcome-to-itns-new-7-year-grant-award-period https://www.immunetolerance.org/news-immunetolerance-org/welcome-to-our-new-look https://www.immunetolerance.org/clinical-trials/a-cooperative-clinical-study-of-abatacept-in-multiple-sclerosis-acclaim https://www.immunetolerance.org/clinical-trials/a-phase-i-study-safety-of-rg2077-ctla4-igg4m-in-patients-with-relapsing-remitting-multiple-sclerosis https://www.immunetolerance.org/clinical-trials/a-research-trial-of-aralast-in-new-onset-diabetes-retain---part-i https://www.immunetolerance.org/clinical-trials/a-screening-study-for-identification-of-tolerance-markers-in-liver-transplant-recipients-who-received-campath-1h-immunosuppression https://www.immunetolerance.org/clinical-trials/a-study-to-determine-the-immunogenicity-and-oral-tolerance-to-keyhole-limpet-hemocyanin-klh-take https://www.immunetolerance.org/clinical-trials/abatacept-and-cyclophosphamide-combination-therapy-for-lupus-nephritis-access https://www.immunetolerance.org/clinical-trials/allergen-iss-conjugates-in-allergic-rhinitis https://www.immunetolerance.org/clinical-trials/anti-tslp-plus-antigen-specific-immunotherapy-for-induction-of-tolerance-in-individuals-with-cat-allergy-catnip https://www.immunetolerance.org/clinical-trials/associating-renal-transplantation-with-the-itn-signature-of-tolerance-artist https://www.immunetolerance.org/clinical-trials/atorvastatin-lipitor-therapy-in-patients-with-clinically-isolated-syndrome-cis-at-risk-for-multiple-sclerosis-staycis https://www.immunetolerance.org/clinical-trials/autoantigen-vaccination-in-human-type-1-newly-diagnosed-diabetes-mellitus https://www.immunetolerance.org/clinical-trials/autoimmunity-blocking-antibody-for-tolerance-in-recently-diagnosed-type-1-diabetes-abate https://www.immunetolerance.org/clinical-trials/belatacept-to-prevent-organ-rejection-in-kidney-transplant-patients https://www.immunetolerance.org/clinical-trials/campath-1h-tacrolimus-sirolimus-withdrawal-in-renal-transplantation https://www.immunetolerance.org/clinical-trials/cat-pilot-study---environmental-exposure-chamber-eec-vs-nasal-allergen-challenge-nac-cat-eec-study https://www.immunetolerance.org/clinical-trials/cytokine-production-in-children-with-pre-clinical-and-clinical-type-1-insulin-dependent-diabetes-mellitus-abba https://www.immunetolerance.org/clinical-trials/efficacy-and-safety-evaluation-of-allergen-immunotherapy-co-administered-with-omalizumab-an-anti-ige-monoclonal-antibody https://www.immunetolerance.org/clinical-trials/efficacy-of-ustekinumab-followed-by-abatacept-for-the-treatment-of-psoriasis-vulgaris-pause https://www.immunetolerance.org/clinical-trials/evaluation-of-donor-specific-immune-senescence-and-exhaustion-as-biomarkers-of-tolerance-post-liver-transplantation-optimal https://www.immunetolerance.org/clinical-trials/follow-up-of-individual-t-cell-mobilization-through-tcr-integration https://www.immunetolerance.org/clinical-trials/gradual-withdrawal-of-immune-system-suppressing-drugs-in-patients-receiving-a-liver-transplant-a-wish https://www.immunetolerance.org/clinical-trials/grass-pollen-immunotherapy-plus-dupilumab-for-tolerance-induction-graduate https://www.immunetolerance.org/clinical-trials/high-dose-immunosuppression-and-autologous-transplantation-for-multiple-sclerosis-halt-ms https://www.immunetolerance.org/clinical-trials/immune-system-suppression-with-alemtuzumab-and-tacrolimus-in-liver-transplantation-patients-tilt https://www.immunetolerance.org/clinical-trials/immunosuppressive-medications-for-participants-in-itn005ct-exiist https://www.immunetolerance.org/clinical-trials/inducing-remission-in-new-onset-t1dm-with-alefacept-amevive-r-t1dal https://www.immunetolerance.org/clinical-trials/mechanistic-studies-in-a-phase-ii-trial-of-multiple-sclerosis-with-altered-peptide-ligand-apl https://www.immunetolerance.org/clinical-trials/mixed-chimerism-and-renal-allograft-with-non-myeloablative-conditioning-in-patients-with-esrd-due-to-multiple-myeloma https://www.immunetolerance.org/clinical-trials/mixed-chimerism-i-renal-allograft-tolerance-through-mixed-chimerism https://www.immunetolerance.org/clinical-trials/mixed-chimerism-ii-renal-allograft-tolerance-through-mixed-chimerism https://www.immunetolerance.org/clinical-trials/monitoring-of-cmv-specific-t-cells-following-tolerance-induction-protocols-a-safety-approach https://www.immunetolerance.org/clinical-trials/multicenter-trial-of-islet-transplantation-in-type-1-diabetic-patients-using-the-edmonton-protocol https://www.immunetolerance.org/clinical-trials/persistence-of-oral-tolerance-to-peanut-leap-on https://www.immunetolerance.org/clinical-trials/pilot-study-using-donor-stem-cells-and-campath-1h-to-induce-renal-transplant-tolerance https://www.immunetolerance.org/clinical-trials/post-transplant-cyclophosphamide-acceptor https://www.immunetolerance.org/clinical-trials/preserving-beta-cell-function-with-tocilizumab-in-new-onset-type-1-diabetes-extend https://www.immunetolerance.org/clinical-trials/proleukin-r-and-rapamune-r-in-type-1-diabetes-mellitus-il2-rapa https://www.immunetolerance.org/clinical-trials/promoting-tolerance-to-common-allergens-in-high-risk-children-global-prevention-of-asthma-in-children-gpac-study https://www.immunetolerance.org/clinical-trials/promoting-tolerance-to-peanut-in-high-risk-children-leap https://www.immunetolerance.org/clinical-trials/research-study-of-atg-and-rituximab-in-renal-transplantation-restarrt https://www.immunetolerance.org/clinical-trials/rituximab-for-the-treatment-of-wegeners-granulomatosis-and-microscopic-polyangiitis-rave https://www.immunetolerance.org/clinical-trials/study-of-antithymocyte-globulin-for-treatment-of-new-onset-t1dm-start https://www.immunetolerance.org/clinical-trials/study-of-tolerant-kidney-transplant-recipients-factor https://www.immunetolerance.org/clinical-trials/treatment-of-psoriatic-arthritis-with-hokt3g-ala-ala-psoriatic-arthritis-research-trial-part https://www.immunetolerance.org/clinical-trials/trial--1 https://www.immunetolerance.org/clinical-trials/trial-108 https://www.immunetolerance.org/clinical-trials/trial-109 https://www.immunetolerance.org/clinical-trials/trial-11 https://www.immunetolerance.org/clinical-trials/trial-110 https://www.immunetolerance.org/clinical-trials/trial-113 https://www.immunetolerance.org/clinical-trials/trial-115 https://www.immunetolerance.org/clinical-trials/trial-120 https://www.immunetolerance.org/clinical-trials/trial-121 https://www.immunetolerance.org/clinical-trials/trial-122 https://www.immunetolerance.org/clinical-trials/trial-123 https://www.immunetolerance.org/clinical-trials/trial-125 https://www.immunetolerance.org/clinical-trials/trial-128 https://www.immunetolerance.org/clinical-trials/trial-133 https://www.immunetolerance.org/clinical-trials/trial-135 https://www.immunetolerance.org/clinical-trials/trial-136 https://www.immunetolerance.org/clinical-trials/trial-138 https://www.immunetolerance.org/clinical-trials/trial-139 https://www.immunetolerance.org/clinical-trials/trial-143 https://www.immunetolerance.org/clinical-trials/trial-144 https://www.immunetolerance.org/clinical-trials/trial-146 https://www.immunetolerance.org/clinical-trials/trial-147 https://www.immunetolerance.org/clinical-trials/trial-148 https://www.immunetolerance.org/clinical-trials/trial-149 https://www.immunetolerance.org/clinical-trials/trial-150 https://www.immunetolerance.org/clinical-trials/trial-151 https://www.immunetolerance.org/clinical-trials/trial-152 https://www.immunetolerance.org/clinical-trials/trial-155 https://www.immunetolerance.org/clinical-trials/trial-156 https://www.immunetolerance.org/clinical-trials/trial-16 https://www.immunetolerance.org/clinical-trials/trial-17 https://www.immunetolerance.org/clinical-trials/trial-18 https://www.immunetolerance.org/clinical-trials/trial-19 https://www.immunetolerance.org/clinical-trials/trial-28 https://www.immunetolerance.org/clinical-trials/trial-33 https://www.immunetolerance.org/clinical-trials/trial-3478 https://www.immunetolerance.org/clinical-trials/trial-3479 https://www.immunetolerance.org/clinical-trials/trial-3483 https://www.immunetolerance.org/clinical-trials/trial-3484 https://www.immunetolerance.org/clinical-trials/trial-3485 https://www.immunetolerance.org/clinical-trials/trial-3486 https://www.immunetolerance.org/clinical-trials/trial-3489 https://www.immunetolerance.org/clinical-trials/trial-3490 https://www.immunetolerance.org/clinical-trials/trial-3491 https://www.immunetolerance.org/clinical-trials/trial-3493 https://www.immunetolerance.org/clinical-trials/trial-3495 https://www.immunetolerance.org/clinical-trials/trial-3496 https://www.immunetolerance.org/clinical-trials/trial-3497 https://www.immunetolerance.org/clinical-trials/trial-3499 https://www.immunetolerance.org/clinical-trials/trial-35 https://www.immunetolerance.org/clinical-trials/trial-3500 https://www.immunetolerance.org/clinical-trials/trial-3503 https://www.immunetolerance.org/clinical-trials/trial-3504 https://www.immunetolerance.org/clinical-trials/trial-3505 https://www.immunetolerance.org/clinical-trials/trial-3507 https://www.immunetolerance.org/clinical-trials/trial-3508 https://www.immunetolerance.org/clinical-trials/trial-3509 https://www.immunetolerance.org/clinical-trials/trial-3510 https://www.immunetolerance.org/clinical-trials/trial-3512 https://www.immunetolerance.org/clinical-trials/trial-3513 https://www.immunetolerance.org/clinical-trials/trial-3514 https://www.immunetolerance.org/clinical-trials/trial-37 https://www.immunetolerance.org/clinical-trials/trial-4 https://www.immunetolerance.org/clinical-trials/trial-40 https://www.immunetolerance.org/clinical-trials/trial-41 https://www.immunetolerance.org/clinical-trials/trial-42 https://www.immunetolerance.org/clinical-trials/trial-43 https://www.immunetolerance.org/clinical-trials/trial-44 https://www.immunetolerance.org/clinical-trials/trial-45 https://www.immunetolerance.org/clinical-trials/trial-46 https://www.immunetolerance.org/clinical-trials/trial-47 https://www.immunetolerance.org/clinical-trials/trial-49 https://www.immunetolerance.org/clinical-trials/trial-5 https://www.immunetolerance.org/clinical-trials/trial-50 https://www.immunetolerance.org/clinical-trials/trial-51 https://www.immunetolerance.org/clinical-trials/trial-54 https://www.immunetolerance.org/clinical-trials/trial-55 https://www.immunetolerance.org/clinical-trials/trial-56 https://www.immunetolerance.org/clinical-trials/trial-58 https://www.immunetolerance.org/clinical-trials/trial-59 https://www.immunetolerance.org/clinical-trials/trial-6 https://www.immunetolerance.org/clinical-trials/trial-61 https://www.immunetolerance.org/clinical-trials/trial-62 https://www.immunetolerance.org/clinical-trials/trial-65 https://www.immunetolerance.org/clinical-trials/trial-66 https://www.immunetolerance.org/clinical-trials/trial-68 https://www.immunetolerance.org/clinical-trials/trial-70 https://www.immunetolerance.org/clinical-trials/trial-71 https://www.immunetolerance.org/clinical-trials/trial-73 https://www.immunetolerance.org/clinical-trials/trial-75 https://www.immunetolerance.org/clinical-trials/trial-76 https://www.immunetolerance.org/clinical-trials/trial-79 https://www.immunetolerance.org/clinical-trials/trial-80 https://www.immunetolerance.org/clinical-trials/trial-81 https://www.immunetolerance.org/clinical-trials/trial-83 https://www.immunetolerance.org/clinical-trials/trial-84 https://www.immunetolerance.org/clinical-trials/trial-85 https://www.immunetolerance.org/clinical-trials/trial-86 https://www.immunetolerance.org/clinical-trials/trial-87 https://www.immunetolerance.org/clinical-trials/trial-88 https://www.immunetolerance.org/clinical-trials/trial-89 https://www.immunetolerance.org/clinical-trials/trial-9 https://www.immunetolerance.org/clinical-trials/trial-90 https://www.immunetolerance.org/clinical-trials/trial-91 https://www.immunetolerance.org/clinical-trials/trial-92 https://www.immunetolerance.org/clinical-trials/trial-94 https://www.immunetolerance.org/clinical-trials/withdrawal-of-immunosuppression-in-pediatric-liver-transplant-recipients-wisp-r https://www.immunetolerance.org/core-laboratories/blood-transcriptomics-repertoire-core https://www.immunetolerance.org/core-laboratories/epigenetics-core https://www.immunetolerance.org/core-laboratories/flow-cytometry-cytof https://www.immunetolerance.org/core-laboratories/genomics-core https://www.immunetolerance.org/core-laboratories/high-throughput-immunosequencing-core https://www.immunetolerance.org/core-laboratories/hla-typing-nucleic-isolation-core https://www.immunetolerance.org/core-laboratories/immunological-diagnostic-testing-core https://www.immunetolerance.org/core-laboratories/tetramer-core https://www.immunetolerance.org/core-laboratories/tissue-pathology-core-at-upmc https://www.immunetolerance.org/core-laboratories/type-1-diabetes-autoantibody-core https://www.immunetolerance.org/member-portal/news-member-portal/18-month-data-from-rave-trial-to-be-reported-this-week-at-acr https://www.immunetolerance.org/member-portal/news-member-portal/2012-annual-technical-report-deadline-approaching https://www.immunetolerance.org/member-portal/news-member-portal/2012-kick-off https://www.immunetolerance.org/member-portal/news-member-portal/2012-performance-evaluations-now-available https://www.immunetolerance.org/member-portal/news-member-portal/2013-employee-evaluations-now-available https://www.immunetolerance.org/member-portal/news-member-portal/2016-year-end-summary https://www.immunetolerance.org/member-portal/news-member-portal/a-potential-test-tube-assay-for-food-allergy https://www.immunetolerance.org/member-portal/news-member-portal/a-strong-association-between-malt1-locus-and-peanut-allergy https://www.immunetolerance.org/member-portal/news-member-portal/a-transplant-breakthrough-by-itn-investigators https://www.immunetolerance.org/member-portal/news-member-portal/a-view-towards-immune-tolerance---a-five-part-series https://www.immunetolerance.org/member-portal/news-member-portal/a-view-towards-immune-tolerance---part-2 https://www.immunetolerance.org/member-portal/news-member-portal/a-view-towards-immune-tolerance---part-3 https://www.immunetolerance.org/member-portal/news-member-portal/a-view-towards-immune-tolerance---part-4 https://www.immunetolerance.org/member-portal/news-member-portal/a-view-towards-immune-tolerance---part-5 https://www.immunetolerance.org/member-portal/news-member-portal/aaron-gannon---december-2011-achiever-award-winner https://www.immunetolerance.org/member-portal/news-member-portal/aaron-gannon-promoted-to-director-of-it-operations https://www.immunetolerance.org/member-portal/news-member-portal/abatacept-for-lupus-nephritis-the-access-study https://www.immunetolerance.org/member-portal/news-member-portal/abatacept-in-relapsing-remitting-multiple-sclerosis https://www.immunetolerance.org/member-portal/news-member-portal/acceptor-kidney-transplant-study-opens-for-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/access-lupus-nephritis-study-completes-enrollment-early https://www.immunetolerance.org/member-portal/news-member-portal/achiever-award-for-q3-michael-konieczny https://www.immunetolerance.org/member-portal/news-member-portal/activate-study-investigating-microbiome-exposure-in-c-section-infants-and-allergy-development-begins-recruitment https://www.immunetolerance.org/member-portal/news-member-portal/agenda-for-april-2015-itn-nsc-meeting https://www.immunetolerance.org/member-portal/news-member-portal/alefacept-preserves-beta-cell-function-in-some-new-onset-type-1-diabetes-patients-out-to-two-years https://www.immunetolerance.org/member-portal/news-member-portal/allergy-asthma-and-covid-19-susceptibility https://www.immunetolerance.org/member-portal/news-member-portal/american-academy-of-pediatrics-endorses-early-peanut-introduction-based-on-itns-leap-study https://www.immunetolerance.org/member-portal/news-member-portal/american-diabetes-associations-71st-scientific-sessions https://www.immunetolerance.org/member-portal/news-member-portal/an-update-on-tolerant-kidney-transplant-recipients https://www.immunetolerance.org/member-portal/news-member-portal/announcing-the-itn-member-portal https://www.immunetolerance.org/member-portal/news-member-portal/antithymocyte-globulin-in-type-1-diabetes-two-year-results-from-the-start-study https://www.immunetolerance.org/member-portal/news-member-portal/april-2012-nsc-meeting-summary https://www.immunetolerance.org/member-portal/news-member-portal/april-2013-network-steering-committee-meeting-recap https://www.immunetolerance.org/member-portal/news-member-portal/august-17-deadline-for-allergy-and-asthma-concept-proposals https://www.immunetolerance.org/member-portal/news-member-portal/bar-or-wins-2025-dystel-prize---national-ms-society https://www.immunetolerance.org/member-portal/news-member-portal/bdr-is-the-new-department-name-for-tada-trpmo https://www.immunetolerance.org/member-portal/news-member-portal/bdr-mechanistic-operations-announcement https://www.immunetolerance.org/member-portal/news-member-portal/bdr-priorities-and-deadlines-announced https://www.immunetolerance.org/member-portal/news-member-portal/bdr-welcomes-kidan-kebede https://www.immunetolerance.org/member-portal/news-member-portal/beat-ms-a-clinical-trial-of-autologous-hematopoietic-stem-cell-transplantation-versus-best-available-therapy-for-multiple-sclerosis-begins-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/benaroya-research-institutes-jerry-nepom-named-immune-tolerance-network-director https://www.immunetolerance.org/member-portal/news-member-portal/best-wishes-lily https://www.immunetolerance.org/member-portal/news-member-portal/bioshare---biomarker-sample-sharing-opportunity-launched-november-1-2010 https://www.immunetolerance.org/member-portal/news-member-portal/bravos-study-for-scleroderma-begins-recruitment https://www.immunetolerance.org/member-portal/news-member-portal/calibrate-trial-for-lupus-nephritis-opens https://www.immunetolerance.org/member-portal/news-member-portal/call-for-proposals-clinical-trials-of-psoriasis-and-autoimmune-dermatological-disorders https://www.immunetolerance.org/member-portal/news-member-portal/celebrate-ten-years-of-tolerance https://www.immunetolerance.org/member-portal/news-member-portal/chris-larsen-awarded-the-pioneer-award-at-wtc-2025-kjouj https://www.immunetolerance.org/member-portal/news-member-portal/compilation-of-2011-annual-technical-report-to-begin https://www.immunetolerance.org/member-portal/news-member-portal/congratulations-juliete-a-f-silva-ms-phd https://www.immunetolerance.org/member-portal/news-member-portal/ctg-welcomes-aboard-luke-lee https://www.immunetolerance.org/member-portal/news-member-portal/ctg-welcomes-sabrina-hurley-by-way-of-bethesda https://www.immunetolerance.org/member-portal/news-member-portal/data-from-itn-lupus-nephritis-study-to-be-presented-at-upcoming-rheumatology-and-nephrology-conferences https://www.immunetolerance.org/member-portal/news-member-portal/data-from-itn-rave-study-to-be-presented-at-american-college-of-rheumatology-meeting https://www.immunetolerance.org/member-portal/news-member-portal/december-update-funding-renewal-faqs https://www.immunetolerance.org/member-portal/news-member-portal/docushare-shut-down https://www.immunetolerance.org/member-portal/news-member-portal/dr-jerry-nepom-receives-2017-george-eisenbarth-award https://www.immunetolerance.org/member-portal/news-member-portal/dr-kristina-harris-has-newly-joined-bdr https://www.immunetolerance.org/member-portal/news-member-portal/drs-nepom-and-corren-discuss-the-catnip-study-with-radio-pet-lady-tracie-hotchner https://www.immunetolerance.org/member-portal/news-member-portal/durable-hay-fever-suppression-may-require-three-years-of-immunotherapy https://www.immunetolerance.org/member-portal/news-member-portal/early-consumption-of-peanuts-prevents-peanut-allergy-in-high-risk-infants https://www.immunetolerance.org/member-portal/news-member-portal/expert-panel-on-food-allergies https://www.immunetolerance.org/member-portal/news-member-portal/extend-study-video-now-available https://www.immunetolerance.org/member-portal/news-member-portal/extension-of-the-pediatric-liver-transplantation-trial-is-planned-for-immunosuppression-withdrawn-participants-reaching-the-end-of-the-two-year-observation-period https://www.immunetolerance.org/member-portal/news-member-portal/fall-2011-nsc-meeting-highlights https://www.immunetolerance.org/member-portal/news-member-portal/fall-2014-itn-network-steering-committee-nsc-meeting-dates https://www.immunetolerance.org/member-portal/news-member-portal/fall-2015-network-steering-committee-meeting-october-13-14-2015 https://www.immunetolerance.org/member-portal/news-member-portal/farewell-to-jenice-dcosta https://www.immunetolerance.org/member-portal/news-member-portal/farewell-to-sachin-malhotra https://www.immunetolerance.org/member-portal/news-member-portal/farewell-to-winnie-felix https://www.immunetolerance.org/member-portal/news-member-portal/fda-panel https://www.immunetolerance.org/member-portal/news-member-portal/first-beat-ms-participant-has-been-enrolled-and-randomized https://www.immunetolerance.org/member-portal/news-member-portal/first-patient-transplanted-in-the-acceptor-study https://www.immunetolerance.org/member-portal/news-member-portal/first-subject-transplanted-in-expanded-study-of-mixed-chimerism-in-kidney-transplantation https://www.immunetolerance.org/member-portal/news-member-portal/five-year-follow-up-of-wisp-r-pediatric-liver-transplant-recipients https://www.immunetolerance.org/member-portal/news-member-portal/fond-farewell-to-carol-genseal https://www.immunetolerance.org/member-portal/news-member-portal/gideon-one-of-time100-most-influential-people-in-health https://www.immunetolerance.org/member-portal/news-member-portal/goodbye-and-best-wishes-to-stephanie-chan https://www.immunetolerance.org/member-portal/news-member-portal/goodbye-and-good-luck-michele-cherian https://www.immunetolerance.org/member-portal/news-member-portal/grass-durham-study-of-grass-pollen-allergy-in-uk-enters-enrollment-phase https://www.immunetolerance.org/member-portal/news-member-portal/grass-hay-fever-study-completes-enrollment-early https://www.immunetolerance.org/member-portal/news-member-portal/grass-mechanistic-manuscript-highlighted-as-jaci-editors-choice https://www.immunetolerance.org/member-portal/news-member-portal/halt-ms-data-to-be-presented-at-the-american-society-of-hematology-annual-meeting https://www.immunetolerance.org/member-portal/news-member-portal/halt-ms-therapy-effective-for-inducing-long-term-sustained-remission-of-ms-through-5-years-after-transplant https://www.immunetolerance.org/member-portal/news-member-portal/immune-tolerance-networks-itn-trialshare-wins-national-academies-board-on-research-data-and-information-challenge https://www.immunetolerance.org/member-portal/news-member-portal/immunotherapy-research-in-seattle-and-the-itn https://www.immunetolerance.org/member-portal/news-member-portal/impact-study-for-peanut-allergy-completes-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/impact-study-launches-today-peanut-oral-immunotherapy-in-young-children https://www.immunetolerance.org/member-portal/news-member-portal/in-memory-of-george-eisenbarth-md https://www.immunetolerance.org/member-portal/news-member-portal/introducing-new-bdr-senior-director-michael-howell-phd https://www.immunetolerance.org/member-portal/news-member-portal/itn-achieves-scientific-manuscript-first---provides-open-interactive-access-to-clinical-trial-data-with-new-publication-rituximab-therapy-effective-for-anca-associated-vasculitis https://www.immunetolerance.org/member-portal/news-member-portal/itn-allergy-data-to-be-presented-at-eaaci https://www.immunetolerance.org/member-portal/news-member-portal/itn-allergy-mechanistic-data-at-aaaai-annual-meeting https://www.immunetolerance.org/member-portal/news-member-portal/itn-and-bri-exchange-federation https://www.immunetolerance.org/member-portal/news-member-portal/itn-announces-enrollment-of-first-participant-in-t1dal-trial-for-people-recently-diagnosed-with-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/itn-announces-enrollment-of-first-patient-in-part-i-of-the-retain-trial-for-newly-diagnosed-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/itn-announces-enrollment-of-first-patient-in-phase-ii-trial-for-relapsing-remitting-multiple-sclerosis https://www.immunetolerance.org/member-portal/news-member-portal/itn-bioinformatics-group-wins-partners-in-excellence-award https://www.immunetolerance.org/member-portal/news-member-portal/itn-completes-enrollment-in-pediatric-liver-transplantation-study https://www.immunetolerance.org/member-portal/news-member-portal/itn-completes-enrollment-of-abate-trial-of-teplizumab-in-new-onset-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/itn-director-bluestone-appointed-executive-vice-chancellor-and-provost-at-ucsf https://www.immunetolerance.org/member-portal/news-member-portal/itn-hayfever-pilot-study-data-to-be-presented-at-world-allergy-congress https://www.immunetolerance.org/member-portal/news-member-portal/itn-helped-support-mechanistic-studies-in-new-t1d-immunotherapy-publication https://www.immunetolerance.org/member-portal/news-member-portal/itn-hosts-a-view-towards-immune-tolerance-symposium-at-focis-2012 https://www.immunetolerance.org/member-portal/news-member-portal/itn-job-posting-director-of-biomarker-discovery-research https://www.immunetolerance.org/member-portal/news-member-portal/itn-launches-the-catnip-cat-allergy-immunotherapy-study https://www.immunetolerance.org/member-portal/news-member-portal/itn-launches-the-pause-study-in-psoriasis https://www.immunetolerance.org/member-portal/news-member-portal/itn-leap-trial-cited-in-new-york-times-report-about-the-drop-in-peanut-allergy https://www.immunetolerance.org/member-portal/news-member-portal/itn-mentioned-in-article-about-immunotherapy-research-in-seattle https://www.immunetolerance.org/member-portal/news-member-portal/itn-mourns-the-passing-of-lloyd-mayer https://www.immunetolerance.org/member-portal/news-member-portal/itn-multiple-sclerosis-trial-data-to-be-presented-at-american-society-of-hematology-annual-meeting https://www.immunetolerance.org/member-portal/news-member-portal/itn-network-director-mark-anderson-receives-william-b-coley-award https://www.immunetolerance.org/member-portal/news-member-portal/itn-opens-alltol-study-for-organ-transplant-recipients https://www.immunetolerance.org/member-portal/news-member-portal/itn-opens-anca-associated-vasculitis-biomarker-study-in-the-uk https://www.immunetolerance.org/member-portal/news-member-portal/itn-opens-pilot-study-to-compare-allergen-challenge-methods-cat-eec-study https://www.immunetolerance.org/member-portal/news-member-portal/itn-opens-the-extend-study-in-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/itn-opens-the-optimal-study-for-liver-transplant-recipients https://www.immunetolerance.org/member-portal/news-member-portal/itn-peanut-allergy-prevention-study-highlighted-in-the-wall-street-journal https://www.immunetolerance.org/member-portal/news-member-portal/itn-research-forum-presentation-videos-available-in-member-portal-library https://www.immunetolerance.org/member-portal/news-member-portal/itn-scheduler https://www.immunetolerance.org/member-portal/news-member-portal/itn-study-published-in-jama-shows-successful-immunosuppression-weaning-in-pediatric-liver-recipients https://www.immunetolerance.org/member-portal/news-member-portal/itn-transplant-data-at-american-transplant-congress-2012 https://www.immunetolerance.org/member-portal/news-member-portal/itn-transplant-data-to-be-presented-at-american-transplant-congress-atc-meeting-in-seattle-wa https://www.immunetolerance.org/member-portal/news-member-portal/itn-trialshare-absorbs-bioshare https://www.immunetolerance.org/member-portal/news-member-portal/itn-trialshare-is-highlighted-as-top-story-in-clinical-informatics-news https://www.immunetolerance.org/member-portal/news-member-portal/itn-trialshare-sees-public-usage-rise-following-publication-of-the-first-manuscript-with-embedded-links-to-the-system https://www.immunetolerance.org/member-portal/news-member-portal/itn-type-1-diabetes-data-to-be-featured-at-the-american-diabetes-association-ada-scientific-sessions https://www.immunetolerance.org/member-portal/news-member-portal/itn-type-1-diabetes-roundup-at-the-international-diabetes-federation-idf-and-immunology-of-diabetes-society-ids-meetings https://www.immunetolerance.org/member-portal/news-member-portal/itn-vitiligo-clinical-trial-in-the-news https://www.immunetolerance.org/member-portal/news-member-portal/itn-vitiligo-clinical-trial-reveal-in-the-news https://www.immunetolerance.org/member-portal/news-member-portal/itn-will-receive-national-academies-award-for-trialshare-on-october-23rd https://www.immunetolerance.org/member-portal/news-member-portal/itn-wins-nih-award-for-collaborative-network-for-tolerance-research https://www.immunetolerance.org/member-portal/news-member-portal/itn-year-in-review https://www.immunetolerance.org/member-portal/news-member-portal/itn034ai-access-trial-enrollment-n-100 https://www.immunetolerance.org/member-portal/news-member-portal/itns-access-trial-for-lupus-nephritis-enrolls-first-patient https://www.immunetolerance.org/member-portal/news-member-portal/itns-cateec-article-selected-as-editors-choice-feature-by-jaci https://www.immunetolerance.org/member-portal/news-member-portal/itns-christian-larsen-m-d-d-phil-presented-with-ama-scientific-achievement-award https://www.immunetolerance.org/member-portal/news-member-portal/itns-christian-larsen-md-dphil-presented-with-ama-scientific-achievement-award https://www.immunetolerance.org/member-portal/news-member-portal/itns-leap-and-halt-ms-trials-included-in-niaids-15-selected-research-advances-for-2015 https://www.immunetolerance.org/member-portal/news-member-portal/itns-leap-study-continues-to-influence-dietary-guidance-for-infants-as-well-as-product-development https://www.immunetolerance.org/member-portal/news-member-portal/itns-leap-study-manuscript-has-been-selected-as-one-of-the-most-notable-articles-of-2015 https://www.immunetolerance.org/member-portal/news-member-portal/itns-leap-study-of-peanut-allergy-completes-enrollment-of-640-children https://www.immunetolerance.org/member-portal/news-member-portal/itns-leap-study-recognized-by-society-for-clinical-trials https://www.immunetolerance.org/member-portal/news-member-portal/itns-reboot-study-for-primary-membranous-nephropathy-has-first-patient-visit https://www.immunetolerance.org/member-portal/news-member-portal/itns-start-study-of-newly-diagnosed-type-1-diabetes-begins-pediatric-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/itns-trialshare-wins-honorable-mention-at-bio-it-world-best-practices-awards https://www.immunetolerance.org/member-portal/news-member-portal/jason-woods-departure https://www.immunetolerance.org/member-portal/news-member-portal/job-opening-technical-support-analyst https://www.immunetolerance.org/member-portal/news-member-portal/july-itn-directors-f2f-meeting-at-bri-in-seattle-wa https://www.immunetolerance.org/member-portal/news-member-portal/just-released-funding-renewal-faqs https://www.immunetolerance.org/member-portal/news-member-portal/kidney-graft-function-and-a-b-cell-signature https://www.immunetolerance.org/member-portal/news-member-portal/kidney-transplant-tolerance-signatures-published-in-two-separate-jci-reports https://www.immunetolerance.org/member-portal/news-member-portal/kidney-transplantation-observation-study-completes-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/landmark-study-of-islet-transplantation-reveals-potential-benefits-in-uncontrolled-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/largest-immunosuppression-withdrawal-trial-in-liver-transplant-recipients-undertaken-by-itn-completes-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/last-patient-in-greenbaum-il2-rapa-combination-study-completed-primary-endpoint-visit https://www.immunetolerance.org/member-portal/news-member-portal/last-patient-last-visit-for-impact-trial https://www.immunetolerance.org/member-portal/news-member-portal/latest-results-from-international-islet-transplant-study-confirm-potential-patient-benefits https://www.immunetolerance.org/member-portal/news-member-portal/leap-participant-follow-up-study-publication https://www.immunetolerance.org/member-portal/news-member-portal/leap-reveal-roundup https://www.immunetolerance.org/member-portal/news-member-portal/leap-trio-study---washington-post https://www.immunetolerance.org/member-portal/news-member-portal/letter-from-jerry https://www.immunetolerance.org/member-portal/news-member-portal/letter-from-jerry-2 https://www.immunetolerance.org/member-portal/news-member-portal/letter-from-jerry-3 https://www.immunetolerance.org/member-portal/news-member-portal/letter-from-jerry-4 https://www.immunetolerance.org/member-portal/news-member-portal/letter-from-jerry-5 https://www.immunetolerance.org/member-portal/news-member-portal/letter-from-jerry-6 https://www.immunetolerance.org/member-portal/news-member-portal/littmus-clinical-trial-is-open https://www.immunetolerance.org/member-portal/news-member-portal/littmus-trial-announces-first-liver-transplant https://www.immunetolerance.org/member-portal/news-member-portal/may-itn-network-steering-committee-will-not-meet-in-person https://www.immunetolerance.org/member-portal/news-member-portal/may-nsc-meeting-presentation-slides-posted-for-committee-members https://www.immunetolerance.org/member-portal/news-member-portal/may-nsc-meeting-presentation-slides-posted-for-committee-members-2 https://www.immunetolerance.org/member-portal/news-member-portal/mechanisms-of-tolerance-symposium-at-annual-focis-meeting https://www.immunetolerance.org/member-portal/news-member-portal/message-from-dr-larry-turka https://www.immunetolerance.org/member-portal/news-member-portal/mitzi-dooley-will-be-leaving-the-itn-july-25-2012 https://www.immunetolerance.org/member-portal/news-member-portal/mourning-the-loss-of-dr-josh-levitsky https://www.immunetolerance.org/member-portal/news-member-portal/new-5-year-15-million-research-grant-program-to-accelerate-immune-tolerance-therapies-for-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/new-corporate-graphic-standards https://www.immunetolerance.org/member-portal/news-member-portal/new-hire-aditya-badhwar https://www.immunetolerance.org/member-portal/news-member-portal/new-hire-robert-yates https://www.immunetolerance.org/member-portal/news-member-portal/new-hr-operations-analyst https://www.immunetolerance.org/member-portal/news-member-portal/new-itn-oral-tolerance-pilot-study-enrolls-first-patients https://www.immunetolerance.org/member-portal/news-member-portal/new-itn-powerpoint-templates https://www.immunetolerance.org/member-portal/news-member-portal/new-look-and-features-for-itn-public-website https://www.immunetolerance.org/member-portal/news-member-portal/new-look-for-the-itn-insiders-report https://www.immunetolerance.org/member-portal/news-member-portal/new-member-portal https://www.immunetolerance.org/member-portal/news-member-portal/new-online-pre-screener-for-t1dal-study https://www.immunetolerance.org/member-portal/news-member-portal/new-peanut-allergy-prevention-guidelines-released-based-on-itns-leap-study-results https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-abate-type-1-diabetes-study-reveals-subset-of-patients-with-strong-response-to-therapy https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-angiopoeitin-2-in-anca-associated-vasculitis https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-approaches-to-establishing-tolerance-in-immune-mediated-diseases https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-b-cell-signature-in-tolerant-kidney-transplant-recipients https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-biomarker-study-from-the-rave-trial https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-clinical-outcomes-of-remission-induction-therapy-for-severe-anca-associated-vasculitis https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-differential-induction-of-allergen-specific-iga-responses-following-timothy-grass-subcutaneous-and-sublingual-immunotherapy https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-effect-of-costimulatory-blockade-with-abatacept-after-ustekinumab-withdrawal-in-patients-with-moderate-to-severe-plaque-psoriasis https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-from-catnip-trial-anti-tslp-plus-antigen-specific-immunotherapy-for-induction-of-tolerance-in-individuals-with-cat-allergy https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-from-extend-trial-il-6-receptor-blockade-does-not-slow-v-cell-loss-in-new-onset-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-from-impact-trial-efficacy-and-safety-of-oral-immunotherapy-in-children-aged-1-3-years-with-peanut-allergy https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-grass-pollen-nasal-allergen-challenge-for-assessing-outcomes https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-high-throughput-gene-sequencing-to-estimate-t-cell-populations https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-il-2-and-rapamycin-in-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-indirect-pathway-t-cell-responses-reflect-outcomes-in-kidney-transplant-recipients https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-itn-rave-study-effective-paradigm-for-trials-in-orphan-diseases https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-itns-type-1-diabetes-preclinical-consortiums-first-combination-therapy-study https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-long-term-follow-up-of-islet-transplant-protocol https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-partial-exhaustion-of-cd8-t-cells-in-responders-to-anti-cd3-treatment-in-new-onset-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-predictors-of-peanut-sensitization-to-identify-infants-at-high-risk-for-peanut-allergy https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-results-from-the-t1dal-type-1-diabetes-study https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-start-type-1-diabetes-study-showed-no-difference-in-insulin-production-decline https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-statins-in-multiple-sclerosis https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-t-cell-reconstitution-following-autologous-stem-cell-transplant-in-patients-with-multiple-sclerosis https://www.immunetolerance.org/member-portal/news-member-portal/new-publication-uncovering-pathways-to-personalized-therapies-in-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/new-review-lymphodepletion-and-homeostatic-proliferation-in-transplantation https://www.immunetolerance.org/member-portal/news-member-portal/new-rfp---clinical-trials-of-allogeneic-solid-organ-transplantation-plus-therapeutic-cell-transfer https://www.immunetolerance.org/member-portal/news-member-portal/new-trialshare-hotline https://www.immunetolerance.org/member-portal/news-member-portal/new-white-paper---tolerance-one-transplant-for-life https://www.immunetolerance.org/member-portal/news-member-portal/niaid-launches-online-database-for-global-clinical-researchers https://www.immunetolerance.org/member-portal/news-member-portal/nih-renews-its-dedication-to-fighting-worldwide-asthma https://www.immunetolerance.org/member-portal/news-member-portal/note-from-jerry https://www.immunetolerance.org/member-portal/news-member-portal/nsc-meeting-presentation-slides-posted-for-committee-members https://www.immunetolerance.org/member-portal/news-member-portal/nsc-meeting-updates https://www.immunetolerance.org/member-portal/news-member-portal/nutritional-impact-of-peanut-consumption-in-the-leap-study https://www.immunetolerance.org/member-portal/news-member-portal/october-2012-nsc-meeting-recap https://www.immunetolerance.org/member-portal/news-member-portal/october-2013-nsc-meeting-summary https://www.immunetolerance.org/member-portal/news-member-portal/october-2015-nsc-presentations https://www.immunetolerance.org/member-portal/news-member-portal/online-pre-screen-questionnaire-is-launched-on-acclaim-ms-website https://www.immunetolerance.org/member-portal/news-member-portal/optimal-primary-paper-published https://www.immunetolerance.org/member-portal/news-member-portal/optimal-trial-has-completed-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/part-ib-of-retain-type-1-diabetes-study-opens-for-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/pause-psoriasis-trial-completes-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/pause-study-video-now-available https://www.immunetolerance.org/member-portal/news-member-portal/peanut-allergy-development https://www.immunetolerance.org/member-portal/news-member-portal/pilot-study-seeks-to-understand-biomarkers-in-cat-allergy-response https://www.immunetolerance.org/member-portal/news-member-portal/pilot-study-to-compare-nasal-allergen-challenge-with-environmental-chamber-challenges-cateec-completes-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/please-welcome-new-bdr-scientist-dr-jenice-dcosta https://www.immunetolerance.org/member-portal/news-member-portal/possible-first-new-treatment-for-anca-associated-vasculitis-in-40-years https://www.immunetolerance.org/member-portal/news-member-portal/postponed-deadline-for-performance-evaluations https://www.immunetolerance.org/member-portal/news-member-portal/predicting-peanut-allergy https://www.immunetolerance.org/member-portal/news-member-portal/presentations-from-may-nsc-posted https://www.immunetolerance.org/member-portal/news-member-portal/presentations-from-october-2016-network-steering-committee-meeting https://www.immunetolerance.org/member-portal/news-member-portal/prophylactic-use-of-sublingual-allergen-immunotherapy-in-high-risk-children https://www.immunetolerance.org/member-portal/news-member-portal/protection-against-peanut-allergy-by-early-consumption-persists-following-a-one-year-period-of-peanut-avoidance https://www.immunetolerance.org/member-portal/news-member-portal/public-launch-of-itn-trialshare-the-itns-new-clinical-trials-research-portal https://www.immunetolerance.org/member-portal/news-member-portal/radio-interview-when-should-children-be-introduced-to-peanut-products https://www.immunetolerance.org/member-portal/news-member-portal/rave-study-data-presented-at-16th-international-vasculitis-anca-workshop-in-paris https://www.immunetolerance.org/member-portal/news-member-portal/recommendations-of-itn-jdrf-combination-therapy-assessment-group-published https://www.immunetolerance.org/member-portal/news-member-portal/reduced-hypoglycemic-events-and-improved-glycemic-variability-is-associated-with-c-peptide-preservation-in-new-onset-type-1-diabetes-patients-in-the-t1dal-study https://www.immunetolerance.org/member-portal/news-member-portal/remembering-jean-francois-bach https://www.immunetolerance.org/member-portal/news-member-portal/reminder-august-17-deadline-for-allergy-and-asthma-concept-proposals https://www.immunetolerance.org/member-portal/news-member-portal/request-for-expressions-of-interest-for-innovative-clinical-trials-in-type-1-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/request-for-proposal-mechanistic-assays-on-stored-samples-from-the-grass-trial https://www.immunetolerance.org/member-portal/news-member-portal/request-for-proposals---clinical-trials-in-immune-tolerance https://www.immunetolerance.org/member-portal/news-member-portal/request-for-proposals-clinical-trials-of-immune-tolerance-for-protein-gene-replacement-therapy https://www.immunetolerance.org/member-portal/news-member-portal/request-for-proposals-clinical-trials-of-immune-tolerance-in-solid-organ-transplantation https://www.immunetolerance.org/member-portal/news-member-portal/request-for-proposals-clinical-trials-of-immune-tolerance-in-transplantation-using-deceased-donor-organs https://www.immunetolerance.org/member-portal/news-member-portal/request-for-proposals-combination-therapy-trials-in-allergy-and-asthma https://www.immunetolerance.org/member-portal/news-member-portal/request-for-proposals-itn-seeks-antigen-specific-t-cell-tolerance-assays-for-myelin-associated-antigens-in-multiple-sclerosis https://www.immunetolerance.org/member-portal/news-member-portal/restarrt-primary-paper-published https://www.immunetolerance.org/member-portal/news-member-portal/restoring-the-balance-immunotherapeutic-combinations-for-autoimmune-disease https://www.immunetolerance.org/member-portal/news-member-portal/results-of-itn-insulin-b-chain-study-for-type-1-diabetes-published https://www.immunetolerance.org/member-portal/news-member-portal/results-of-itn-mixed-chimerism-study-in-kidney-transplantation-published-in-new-england-journal-of-medicine https://www.immunetolerance.org/member-portal/news-member-portal/results-of-itn-phase-i-study-of-ctla4ig-in-multiple-sclerosis-published-in-neurology https://www.immunetolerance.org/member-portal/news-member-portal/reveal-study-completes-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/secondary-outcomes-in-leap-on-participants https://www.immunetolerance.org/member-portal/news-member-portal/seeking-proposals-for-clinical-trials-of-desensitization-in-solid-organ-transplantation https://www.immunetolerance.org/member-portal/news-member-portal/specimens-and-funding-for-type-1-diabetes-biomarker-research https://www.immunetolerance.org/member-portal/news-member-portal/spring-2014-network-steering-committee-meeting-may-20-21-2014 https://www.immunetolerance.org/member-portal/news-member-portal/spring-2014-nsc-meeting-in-seattle https://www.immunetolerance.org/member-portal/news-member-portal/start-clinical-trial-press-release-translated-for-inclusion-on-aaas-eurekalert-chinese https://www.immunetolerance.org/member-portal/news-member-portal/stem-cell-transplants-may-halt-progression-of-multiple-sclerosis https://www.immunetolerance.org/member-portal/news-member-portal/stephen-abreu-will-be-parting-from-the-itn https://www.immunetolerance.org/member-portal/news-member-portal/strategic-partnerships-and-business-development-initiative https://www.immunetolerance.org/member-portal/news-member-portal/study-shows-six-injection-allergy-vaccine-tames-hay-fever-for-at-least-two-years https://www.immunetolerance.org/member-portal/news-member-portal/successful-kick-off-meeting-for-itn055ai-calibrate-study-in-lupus-nephritis https://www.immunetolerance.org/member-portal/news-member-portal/t1dal-2-year-clinical-results https://www.immunetolerance.org/member-portal/news-member-portal/t1dal-study-completes-enrollment https://www.immunetolerance.org/member-portal/news-member-portal/t1dal-study-of-alefacept-in-newly-diagnosed-type-1-diabetes-begins-enrollment-to-younger-ages https://www.immunetolerance.org/member-portal/news-member-portal/the-first-activate-baby-has-been-born https://www.immunetolerance.org/member-portal/news-member-portal/the-immune-tolerance-network-opens-anca-associated-vasculitis-biomarker-study-in-the-uk https://www.immunetolerance.org/member-portal/news-member-portal/the-itn-at-the-american-transplant-congress https://www.immunetolerance.org/member-portal/news-member-portal/the-itn-congratulates-the-2025-nobel-prize-in-physiology-or-medicine-winners https://www.immunetolerance.org/member-portal/news-member-portal/transplant-rfp-update-itn-invites-two-applications-for-full-review https://www.immunetolerance.org/member-portal/news-member-portal/type-1-diabetes-data-to-be-presented-at-european-association-for-the-study-of-diabetes https://www.immunetolerance.org/member-portal/news-member-portal/ucsf-members-open-enrollment-announced https://www.immunetolerance.org/member-portal/news-member-portal/update-nih-review-of-um1-renewal-application https://www.immunetolerance.org/member-portal/news-member-portal/updated-brand-names-guide https://www.immunetolerance.org/member-portal/news-member-portal/updated-brand-names-guide-2 https://www.immunetolerance.org/member-portal/news-member-portal/updated-brand-names-guide-3 https://www.immunetolerance.org/member-portal/news-member-portal/updated-itn-word-and-ppt-templates https://www.immunetolerance.org/member-portal/news-member-portal/validated-itn-foxp3-flow-cytometry-methodology-published-graces-cover-of-cytometry-b https://www.immunetolerance.org/member-portal/news-member-portal/welcome-aboard-dr-lijing-xu https://www.immunetolerance.org/member-portal/news-member-portal/welcome-anitha-achyutha https://www.immunetolerance.org/member-portal/news-member-portal/welcome-karen-chia-aparna-shukla-dennis-wightman https://www.immunetolerance.org/member-portal/news-member-portal/welcome-sophia-chang-to-nco https://www.immunetolerance.org/member-portal/news-member-portal/welcome-to-itns-new-7-year-grant-award-period https://www.immunetolerance.org/member-portal/news-member-portal/welcome-to-our-new-look https://www.immunetolerance.org/member-portal-contacts/contacts-27389 https://www.immunetolerance.org/member-portal-contacts/contacts-27432 https://www.immunetolerance.org/member-portal-contacts/contacts-27505 https://www.immunetolerance.org/member-portal-contacts/contacts-27510 https://www.immunetolerance.org/member-portal-contacts/contacts-27526 https://www.immunetolerance.org/member-portal-contacts/contacts-27531 https://www.immunetolerance.org/member-portal-contacts/contacts-27538 https://www.immunetolerance.org/member-portal-contacts/contacts-27604 https://www.immunetolerance.org/member-portal-contacts/contacts-28027 https://www.immunetolerance.org/member-portal-contacts/contacts-28445 https://www.immunetolerance.org/member-portal-contacts/contacts-28707 https://www.immunetolerance.org/member-portal-contacts/contacts-28861 https://www.immunetolerance.org/member-portal-contacts/contacts-29463 https://www.immunetolerance.org/member-portal-contacts/contacts-30386 https://www.immunetolerance.org/member-portal-contacts/contacts-31014 https://www.immunetolerance.org/member-portal-contacts/contacts-31015 https://www.immunetolerance.org/member-portal-contacts/contacts-31337 https://www.immunetolerance.org/member-portal-contacts/contacts-31351 https://www.immunetolerance.org/member-portal-contacts/contacts-31368 https://www.immunetolerance.org/member-portal-contacts/contacts-31374 https://www.immunetolerance.org/member-portal-contacts/contacts-31402 https://www.immunetolerance.org/member-portal-contacts/contacts-31474 https://www.immunetolerance.org/member-portal-contacts/contacts-31478 https://www.immunetolerance.org/member-portal-contacts/contacts-31484 https://www.immunetolerance.org/member-portal-contacts/contacts-31508 https://www.immunetolerance.org/member-portal-contacts/contacts-31531 https://www.immunetolerance.org/member-portal-contacts/contacts-31532 https://www.immunetolerance.org/member-portal-contacts/contacts-31574 https://www.immunetolerance.org/member-portal-contacts/contacts-31575 https://www.immunetolerance.org/member-portal-contacts/contacts-31577 https://www.immunetolerance.org/member-portal-contacts/contacts-31596 https://www.immunetolerance.org/member-portal-contacts/contacts-31600 https://www.immunetolerance.org/member-portal-contacts/contacts-31603 https://www.immunetolerance.org/member-portal-contacts/contacts-31604 https://www.immunetolerance.org/member-portal-contacts/contacts-31620 https://www.immunetolerance.org/member-portal-contacts/contacts-31622 https://www.immunetolerance.org/member-portal-contacts/contacts-31631 https://www.immunetolerance.org/member-portal-contacts/contacts-31649 https://www.immunetolerance.org/member-portal-contacts/contacts-31658 https://www.immunetolerance.org/member-portal-contacts/contacts-31660 https://www.immunetolerance.org/member-portal-contacts/contacts-31683 https://www.immunetolerance.org/member-portal-contacts/contacts-31684 https://www.immunetolerance.org/member-portal-contacts/contacts-31698 https://www.immunetolerance.org/member-portal-contacts/contacts-31701 https://www.immunetolerance.org/member-portal-contacts/contacts-31702 https://www.immunetolerance.org/member-portal-contacts/contacts-31705 https://www.immunetolerance.org/member-portal-contacts/contacts-31724 https://www.immunetolerance.org/member-portal-contacts/contacts-31738 https://www.immunetolerance.org/member-portal-contacts/contacts-31743 https://www.immunetolerance.org/member-portal-contacts/contacts-31747 https://www.immunetolerance.org/member-portal-contacts/contacts-31754 https://www.immunetolerance.org/member-portal-contacts/contacts-31757 https://www.immunetolerance.org/member-portal-contacts/contacts-31769 https://www.immunetolerance.org/member-portal-contacts/contacts-31779 https://www.immunetolerance.org/member-portal-contacts/contacts-31874 https://www.immunetolerance.org/member-portal-contacts/contacts-31882 https://www.immunetolerance.org/member-portal-contacts/contacts-31884 https://www.immunetolerance.org/member-portal-contacts/contacts-31891 https://www.immunetolerance.org/member-portal-contacts/contacts-31898 https://www.immunetolerance.org/member-portal-contacts/contacts-31904 https://www.immunetolerance.org/member-portal-contacts/contacts-31933 https://www.immunetolerance.org/member-portal-contacts/contacts-31973 https://www.immunetolerance.org/member-portal-contacts/contacts-31974 https://www.immunetolerance.org/member-portal-contacts/contacts-32011 https://www.immunetolerance.org/member-portal-contacts/contacts-32012 https://www.immunetolerance.org/member-portal-contacts/contacts-32014 https://www.immunetolerance.org/member-portal-contacts/contacts-32015 https://www.immunetolerance.org/member-portal-contacts/contacts-32032 https://www.immunetolerance.org/member-portal-contacts/contacts-32085 https://www.immunetolerance.org/member-portal-contacts/contacts-32088 https://www.immunetolerance.org/member-portal-contacts/contacts-32130 https://www.immunetolerance.org/member-portal-contacts/contacts-32174 https://www.immunetolerance.org/member-portal-contacts/contacts-32176 https://www.immunetolerance.org/member-portal-contacts/contacts-32177 https://www.immunetolerance.org/member-portal-contacts/contacts-32178 https://www.immunetolerance.org/member-portal-contacts/contacts-32180 https://www.immunetolerance.org/member-portal-contacts/contacts-32181 https://www.immunetolerance.org/member-portal-contacts/contacts-32186 https://www.immunetolerance.org/member-portal-contacts/contacts-32254 https://www.immunetolerance.org/member-portal-contacts/contacts-32255 https://www.immunetolerance.org/member-portal-contacts/contacts-32447 https://www.immunetolerance.org/member-portal-contacts/contacts-32458 https://www.immunetolerance.org/member-portal-contacts/contacts-32564 https://www.immunetolerance.org/member-portal-contacts/contacts-32578 https://www.immunetolerance.org/member-portal-contacts/contacts-32583 https://www.immunetolerance.org/member-portal-contacts/contacts-32591 https://www.immunetolerance.org/member-portal-contacts/contacts-32595 https://www.immunetolerance.org/member-portal-contacts/contacts-32605 https://www.immunetolerance.org/member-portal-contacts/contacts-32610 https://www.immunetolerance.org/member-portal-contacts/contacts-32615 https://www.immunetolerance.org/member-portal-contacts/contacts-32620 https://www.immunetolerance.org/member-portal-contacts/contacts-32623 https://www.immunetolerance.org/member-portal-contacts/contacts-32625 https://www.immunetolerance.org/member-portal-contacts/contacts-32633 https://www.immunetolerance.org/member-portal-contacts/contacts-32635 https://www.immunetolerance.org/member-portal-contacts/contacts-32637 https://www.immunetolerance.org/member-portal-contacts/contacts-32647 https://www.immunetolerance.org/member-portal-contacts/contacts-32649 https://www.immunetolerance.org/member-portal-contacts/contacts-32675 https://www.immunetolerance.org/member-portal-contacts/contacts-32692 https://www.immunetolerance.org/member-portal-contacts/contacts-32695 https://www.immunetolerance.org/member-portal-contacts/contacts-32698 https://www.immunetolerance.org/member-portal-contacts/contacts-32723 https://www.immunetolerance.org/member-portal-contacts/contacts-32729 https://www.immunetolerance.org/member-portal-contacts/contacts-32738 https://www.immunetolerance.org/member-portal-contacts/contacts-32743 https://www.immunetolerance.org/member-portal-contacts/contacts-32745 https://www.immunetolerance.org/member-portal-contacts/contacts-32754 https://www.immunetolerance.org/member-portal-contacts/contacts-32756 https://www.immunetolerance.org/member-portal-contacts/contacts-32758 https://www.immunetolerance.org/member-portal-contacts/contacts-32762 https://www.immunetolerance.org/member-portal-contacts/contacts-32785 https://www.immunetolerance.org/member-portal-contacts/contacts-32843 https://www.immunetolerance.org/member-portal-contacts/contacts-32929 https://www.immunetolerance.org/member-portal-contacts/contacts-32971 https://www.immunetolerance.org/member-portal-contacts/contacts-32976 https://www.immunetolerance.org/member-portal-contacts/contacts-33003 https://www.immunetolerance.org/member-portal-contacts/contacts-33018 https://www.immunetolerance.org/member-portal-contacts/contacts-33021 https://www.immunetolerance.org/member-portal-contacts/contacts-33042 https://www.immunetolerance.org/member-portal-contacts/contacts-33043 https://www.immunetolerance.org/member-portal-contacts/contacts-33044 https://www.immunetolerance.org/member-portal-contacts/contacts-33045 https://www.immunetolerance.org/member-portal-contacts/contacts-33046 https://www.immunetolerance.org/member-portal-contacts/contacts-33047 https://www.immunetolerance.org/member-portal-contacts/contacts-33049 https://www.immunetolerance.org/member-portal-contacts/contacts-33066 https://www.immunetolerance.org/member-portal-contacts/contacts-33081 https://www.immunetolerance.org/member-portal-contacts/contacts-33083 https://www.immunetolerance.org/member-portal-contacts/contacts-33085 https://www.immunetolerance.org/member-portal-contacts/contacts-33086 https://www.immunetolerance.org/member-portal-contacts/contacts-33087 https://www.immunetolerance.org/member-portal-contacts/contacts-33089 https://www.immunetolerance.org/member-portal-contacts/contacts-33090 https://www.immunetolerance.org/member-portal-contacts/contacts-33091 https://www.immunetolerance.org/member-portal-contacts/contacts-33102 https://www.immunetolerance.org/member-portal-contacts/contacts-33107 https://www.immunetolerance.org/member-portal-contacts/contacts-33110 https://www.immunetolerance.org/member-portal-contacts/contacts-33113 https://www.immunetolerance.org/member-portal-contacts/contacts-33121 https://www.immunetolerance.org/member-portal-contacts/contacts-33124 https://www.immunetolerance.org/member-portal-contacts/contacts-33127 https://www.immunetolerance.org/member-portal-contacts/contacts-33131 https://www.immunetolerance.org/member-portal-contacts/contacts-33167 https://www.immunetolerance.org/member-portal-contacts/contacts-33187 https://www.immunetolerance.org/member-portal-contacts/contacts-33193 https://www.immunetolerance.org/member-portal-contacts/contacts-33205 https://www.immunetolerance.org/member-portal-contacts/contacts-33222 https://www.immunetolerance.org/member-portal-contacts/contacts-33227 https://www.immunetolerance.org/member-portal-contacts/contacts-33230 https://www.immunetolerance.org/member-portal-contacts/contacts-33231 https://www.immunetolerance.org/member-portal-contacts/contacts-33234 https://www.immunetolerance.org/member-portal-contacts/contacts-33235 https://www.immunetolerance.org/member-portal-contacts/contacts-33236 https://www.immunetolerance.org/member-portal-contacts/contacts-33237 https://www.immunetolerance.org/member-portal-contacts/contacts-33238 https://www.immunetolerance.org/member-portal-contacts/contacts-33246 https://www.immunetolerance.org/member-portal-contacts/contacts-33248 https://www.immunetolerance.org/member-portal-contacts/contacts-33249 https://www.immunetolerance.org/member-portal-contacts/contacts-33258 https://www.immunetolerance.org/member-portal-contacts/contacts-33269 https://www.immunetolerance.org/member-portal-contacts/contacts-33292 https://www.immunetolerance.org/member-portal-contacts/contacts-33293 https://www.immunetolerance.org/member-portal-contacts/contacts-33298 https://www.immunetolerance.org/member-portal-contacts/contacts-33300 https://www.immunetolerance.org/member-portal-contacts/contacts-33303 https://www.immunetolerance.org/member-portal-contacts/contacts-33312 https://www.immunetolerance.org/member-portal-contacts/contacts-33316 https://www.immunetolerance.org/member-portal-contacts/contacts-33319 https://www.immunetolerance.org/member-portal-contacts/contacts-33321 https://www.immunetolerance.org/member-portal-contacts/contacts-33323 https://www.immunetolerance.org/member-portal-contacts/contacts-33325 https://www.immunetolerance.org/member-portal-contacts/contacts-33327 https://www.immunetolerance.org/member-portal-contacts/contacts-33328 https://www.immunetolerance.org/member-portal-contacts/contacts-33340 https://www.immunetolerance.org/member-portal-contacts/contacts-33348 https://www.immunetolerance.org/member-portal-contacts/contacts-33373 https://www.immunetolerance.org/member-portal-contacts/contacts-33396 https://www.immunetolerance.org/member-portal-contacts/contacts-33449 https://www.immunetolerance.org/member-portal-contacts/contacts-33461 https://www.immunetolerance.org/member-portal-contacts/contacts-33466 https://www.immunetolerance.org/member-portal-contacts/contacts-33470 https://www.immunetolerance.org/member-portal-contacts/contacts-33523 https://www.immunetolerance.org/member-portal-contacts/contacts-33539 https://www.immunetolerance.org/member-portal-contacts/contacts-33611 https://www.immunetolerance.org/member-portal-contacts/contacts-33724 https://www.immunetolerance.org/member-portal-contacts/contacts-33739 https://www.immunetolerance.org/member-portal-contacts/contacts-33822 https://www.immunetolerance.org/member-portal-contacts/contacts-33928 https://www.immunetolerance.org/member-portal-contacts/contacts-34213 https://www.immunetolerance.org/member-portal-contacts/contacts-34214 https://www.immunetolerance.org/member-portal-contacts/contacts-34219 https://www.immunetolerance.org/member-portal-contacts/contacts-34361 https://www.immunetolerance.org/member-portal-contacts/contacts-34364 https://www.immunetolerance.org/member-portal-contacts/contacts-34432 https://www.immunetolerance.org/member-portal-contacts/contacts-34443 https://www.immunetolerance.org/member-portal-contacts/contacts-34448 https://www.immunetolerance.org/member-portal-contacts/contacts-34449 https://www.immunetolerance.org/member-portal-contacts/contacts-34472 https://www.immunetolerance.org/member-portal-contacts/contacts-34527 https://www.immunetolerance.org/member-portal-contacts/contacts-34548 https://www.immunetolerance.org/member-portal-contacts/contacts-34551 https://www.immunetolerance.org/member-portal-contacts/contacts-34552 https://www.immunetolerance.org/member-portal-contacts/contacts-34553 https://www.immunetolerance.org/member-portal-contacts/contacts-34655 https://www.immunetolerance.org/member-portal-contacts/contacts-34656 https://www.immunetolerance.org/member-portal-contacts/contacts-34657 https://www.immunetolerance.org/member-portal-contacts/contacts-34658 https://www.immunetolerance.org/member-portal-contacts/contacts-34659 https://www.immunetolerance.org/member-portal-contacts/contacts-34660 https://www.immunetolerance.org/member-portal-contacts/contacts-34663 https://www.immunetolerance.org/member-portal-contacts/contacts-34667 https://www.immunetolerance.org/member-portal-contacts/contacts-34668 https://www.immunetolerance.org/member-portal-contacts/contacts-34746 https://www.immunetolerance.org/member-portal-contacts/contacts-34753 https://www.immunetolerance.org/member-portal-contacts/contacts-34777 https://www.immunetolerance.org/member-portal-contacts/contacts-35046 https://www.immunetolerance.org/member-portal-contacts/contacts-35064 https://www.immunetolerance.org/member-portal-contacts/contacts-35077 https://www.immunetolerance.org/member-portal-contacts/contacts-35507 https://www.immunetolerance.org/member-portal-contacts/contacts-35587 https://www.immunetolerance.org/member-portal-contacts/contacts-35589 https://www.immunetolerance.org/member-portal-contacts/contacts-35590 https://www.immunetolerance.org/member-portal-contacts/contacts-35591 https://www.immunetolerance.org/member-portal-contacts/contacts-35628 https://www.immunetolerance.org/member-portal-contacts/contacts-35629 https://www.immunetolerance.org/member-portal-contacts/contacts-35630 https://www.immunetolerance.org/member-portal-contacts/contacts-35631 https://www.immunetolerance.org/member-portal-contacts/contacts-35632 https://www.immunetolerance.org/member-portal-contacts/contacts-35633 https://www.immunetolerance.org/member-portal-contacts/contacts-35634 https://www.immunetolerance.org/member-portal-contacts/contacts-35635 https://www.immunetolerance.org/member-portal-contacts/contacts-35636 https://www.immunetolerance.org/member-portal-contacts/contacts-35637 https://www.immunetolerance.org/member-portal-contacts/contacts-35638 https://www.immunetolerance.org/member-portal-contacts/contacts-35639 https://www.immunetolerance.org/member-portal-contacts/contacts-35640 https://www.immunetolerance.org/member-portal-contacts/contacts-35641 https://www.immunetolerance.org/member-portal-contacts/contacts-35642 https://www.immunetolerance.org/member-portal-contacts/contacts-35643 https://www.immunetolerance.org/member-portal-contacts/contacts-35645 https://www.immunetolerance.org/member-portal-contacts/contacts-35646 https://www.immunetolerance.org/member-portal-contacts/contacts-35647 https://www.immunetolerance.org/member-portal-contacts/contacts-35648 https://www.immunetolerance.org/member-portal-contacts/contacts-35649 https://www.immunetolerance.org/member-portal-contacts/contacts-35650 https://www.immunetolerance.org/member-portal-contacts/contacts-35651 https://www.immunetolerance.org/member-portal-contacts/contacts-35652 https://www.immunetolerance.org/member-portal-contacts/contacts-35653 https://www.immunetolerance.org/member-portal-contacts/contacts-35654 https://www.immunetolerance.org/member-portal-contacts/contacts-35655 https://www.immunetolerance.org/member-portal-contacts/contacts-35657 https://www.immunetolerance.org/member-portal-contacts/contacts-35658 https://www.immunetolerance.org/member-portal-contacts/contacts-35662 https://www.immunetolerance.org/member-portal-contacts/contacts-35663 https://www.immunetolerance.org/member-portal-contacts/contacts-35666 https://www.immunetolerance.org/member-portal-contacts/contacts-35667 https://www.immunetolerance.org/member-portal-contacts/contacts-35668 https://www.immunetolerance.org/member-portal-contacts/contacts-35669 https://www.immunetolerance.org/member-portal-contacts/contacts-35670 https://www.immunetolerance.org/member-portal-contacts/contacts-35671 https://www.immunetolerance.org/member-portal-contacts/contacts-35672 https://www.immunetolerance.org/member-portal-contacts/contacts-35673 https://www.immunetolerance.org/member-portal-contacts/contacts-35674 https://www.immunetolerance.org/member-portal-contacts/contacts-35675 https://www.immunetolerance.org/member-portal-contacts/contacts-35676 https://www.immunetolerance.org/member-portal-contacts/contacts-35677 https://www.immunetolerance.org/member-portal-contacts/contacts-35679 https://www.immunetolerance.org/member-portal-contacts/contacts-35680 https://www.immunetolerance.org/member-portal-contacts/contacts-35681 https://www.immunetolerance.org/member-portal-contacts/contacts-35682 https://www.immunetolerance.org/member-portal-contacts/contacts-35683 https://www.immunetolerance.org/member-portal-contacts/contacts-35684 https://www.immunetolerance.org/member-portal-contacts/contacts-35686 https://www.immunetolerance.org/member-portal-contacts/contacts-35687 https://www.immunetolerance.org/member-portal-contacts/contacts-35688 https://www.immunetolerance.org/member-portal-contacts/contacts-35689 https://www.immunetolerance.org/member-portal-contacts/contacts-35690 https://www.immunetolerance.org/member-portal-contacts/contacts-35691 https://www.immunetolerance.org/member-portal-contacts/contacts-35692 https://www.immunetolerance.org/member-portal-contacts/contacts-35693 https://www.immunetolerance.org/member-portal-contacts/contacts-35694 https://www.immunetolerance.org/member-portal-contacts/contacts-35695 https://www.immunetolerance.org/member-portal-contacts/contacts-35697 https://www.immunetolerance.org/member-portal-contacts/contacts-35698 https://www.immunetolerance.org/member-portal-contacts/contacts-35699 https://www.immunetolerance.org/member-portal-contacts/contacts-35700 https://www.immunetolerance.org/member-portal-contacts/contacts-35702 https://www.immunetolerance.org/member-portal-contacts/contacts-35703 https://www.immunetolerance.org/member-portal-contacts/contacts-35706 https://www.immunetolerance.org/member-portal-contacts/contacts-35707 https://www.immunetolerance.org/member-portal-contacts/contacts-35708 https://www.immunetolerance.org/member-portal-contacts/contacts-35709 https://www.immunetolerance.org/member-portal-contacts/contacts-35710 https://www.immunetolerance.org/member-portal-contacts/contacts-35711 https://www.immunetolerance.org/member-portal-contacts/contacts-35712 https://www.immunetolerance.org/member-portal-contacts/contacts-35714 https://www.immunetolerance.org/member-portal-contacts/contacts-35716 https://www.immunetolerance.org/member-portal-contacts/contacts-35717 https://www.immunetolerance.org/member-portal-contacts/contacts-35718 https://www.immunetolerance.org/member-portal-contacts/contacts-35719 https://www.immunetolerance.org/member-portal-contacts/contacts-35720 https://www.immunetolerance.org/member-portal-contacts/contacts-35721 https://www.immunetolerance.org/member-portal-contacts/contacts-35722 https://www.immunetolerance.org/member-portal-contacts/contacts-35723 https://www.immunetolerance.org/member-portal-contacts/contacts-35724 https://www.immunetolerance.org/member-portal-contacts/contacts-35725 https://www.immunetolerance.org/member-portal-contacts/contacts-35726 https://www.immunetolerance.org/member-portal-contacts/contacts-35727 https://www.immunetolerance.org/member-portal-contacts/contacts-35728 https://www.immunetolerance.org/member-portal-contacts/contacts-35729 https://www.immunetolerance.org/member-portal-contacts/contacts-35730 https://www.immunetolerance.org/member-portal-contacts/contacts-35731 https://www.immunetolerance.org/member-portal-contacts/contacts-35732 https://www.immunetolerance.org/member-portal-contacts/contacts-35733 https://www.immunetolerance.org/member-portal-contacts/contacts-35734 https://www.immunetolerance.org/member-portal-contacts/contacts-35735 https://www.immunetolerance.org/member-portal-contacts/contacts-35736 https://www.immunetolerance.org/member-portal-contacts/contacts-35737 https://www.immunetolerance.org/member-portal-contacts/contacts-35767 https://www.immunetolerance.org/member-portal-contacts/contacts-35768 https://www.immunetolerance.org/member-portal-contacts/contacts-35769 https://www.immunetolerance.org/member-portal-contacts/contacts-35847 https://www.immunetolerance.org/member-portal-contacts/contacts-35848 https://www.immunetolerance.org/member-portal-contacts/contacts-35849 https://www.immunetolerance.org/member-portal-contacts/contacts-35874 https://www.immunetolerance.org/member-portal-contacts/contacts-35875 https://www.immunetolerance.org/member-portal-contacts/contacts-36064 https://www.immunetolerance.org/member-portal-contacts/contacts-36079 https://www.immunetolerance.org/member-portal-contacts/contacts-36189 https://www.immunetolerance.org/member-portal-contacts/contacts-36314 https://www.immunetolerance.org/member-portal-contacts/contacts-36365 https://www.immunetolerance.org/member-portal-contacts/contacts-36366 https://www.immunetolerance.org/member-portal-contacts/contacts-36368 https://www.immunetolerance.org/member-portal-contacts/contacts-36373 https://www.immunetolerance.org/member-portal-contacts/contacts-36374 https://www.immunetolerance.org/member-portal-contacts/contacts-36402 https://www.immunetolerance.org/member-portal-contacts/contacts-36441 https://www.immunetolerance.org/member-portal-contacts/contacts-36461 https://www.immunetolerance.org/member-portal-contacts/contacts-36540 https://www.immunetolerance.org/member-portal-contacts/contacts-36541 https://www.immunetolerance.org/member-portal-contacts/contacts-36542 https://www.immunetolerance.org/member-portal-contacts/contacts-36543 https://www.immunetolerance.org/member-portal-contacts/contacts-36544 https://www.immunetolerance.org/member-portal-contacts/contacts-36545 https://www.immunetolerance.org/member-portal-contacts/contacts-36546 https://www.immunetolerance.org/member-portal-contacts/contacts-36547 https://www.immunetolerance.org/member-portal-contacts/contacts-36548 https://www.immunetolerance.org/member-portal-contacts/contacts-36559 https://www.immunetolerance.org/member-portal-contacts/contacts-36565 https://www.immunetolerance.org/member-portal-contacts/contacts-36566 https://www.immunetolerance.org/member-portal-contacts/contacts-36568 https://www.immunetolerance.org/member-portal-contacts/contacts-36572 https://www.immunetolerance.org/member-portal-contacts/contacts-36671 https://www.immunetolerance.org/member-portal-contacts/contacts-36676 https://www.immunetolerance.org/member-portal-contacts/contacts-36763 https://www.immunetolerance.org/member-portal-contacts/contacts-36764 https://www.immunetolerance.org/member-portal-contacts/contacts-36765 https://www.immunetolerance.org/member-portal-contacts/contacts-36766 https://www.immunetolerance.org/member-portal-contacts/contacts-36904 https://www.immunetolerance.org/member-portal-contacts/contacts-37079 https://www.immunetolerance.org/member-portal-contacts/contacts-37130 https://www.immunetolerance.org/member-portal-contacts/contacts-37202 https://www.immunetolerance.org/member-portal-contacts/contacts-37290 https://www.immunetolerance.org/member-portal-studies/study--1 https://www.immunetolerance.org/member-portal-studies/study-1 https://www.immunetolerance.org/member-portal-studies/study-10 https://www.immunetolerance.org/member-portal-studies/study-100 https://www.immunetolerance.org/member-portal-studies/study-101 https://www.immunetolerance.org/member-portal-studies/study-108 https://www.immunetolerance.org/member-portal-studies/study-109 https://www.immunetolerance.org/member-portal-studies/study-11 https://www.immunetolerance.org/member-portal-studies/study-110 https://www.immunetolerance.org/member-portal-studies/study-113 https://www.immunetolerance.org/member-portal-studies/study-115 https://www.immunetolerance.org/member-portal-studies/study-118 https://www.immunetolerance.org/member-portal-studies/study-119 https://www.immunetolerance.org/member-portal-studies/study-12 https://www.immunetolerance.org/member-portal-studies/study-120 https://www.immunetolerance.org/member-portal-studies/study-121 https://www.immunetolerance.org/member-portal-studies/study-122 https://www.immunetolerance.org/member-portal-studies/study-123 https://www.immunetolerance.org/member-portal-studies/study-124 https://www.immunetolerance.org/member-portal-studies/study-125 https://www.immunetolerance.org/member-portal-studies/study-128 https://www.immunetolerance.org/member-portal-studies/study-13 https://www.immunetolerance.org/member-portal-studies/study-133 https://www.immunetolerance.org/member-portal-studies/study-134 https://www.immunetolerance.org/member-portal-studies/study-135 https://www.immunetolerance.org/member-portal-studies/study-136 https://www.immunetolerance.org/member-portal-studies/study-137 https://www.immunetolerance.org/member-portal-studies/study-138 https://www.immunetolerance.org/member-portal-studies/study-139 https://www.immunetolerance.org/member-portal-studies/study-14 https://www.immunetolerance.org/member-portal-studies/study-140 https://www.immunetolerance.org/member-portal-studies/study-141 https://www.immunetolerance.org/member-portal-studies/study-142 https://www.immunetolerance.org/member-portal-studies/study-143 https://www.immunetolerance.org/member-portal-studies/study-144 https://www.immunetolerance.org/member-portal-studies/study-146 https://www.immunetolerance.org/member-portal-studies/study-147 https://www.immunetolerance.org/member-portal-studies/study-148 https://www.immunetolerance.org/member-portal-studies/study-149 https://www.immunetolerance.org/member-portal-studies/study-15 https://www.immunetolerance.org/member-portal-studies/study-150 https://www.immunetolerance.org/member-portal-studies/study-151 https://www.immunetolerance.org/member-portal-studies/study-152 https://www.immunetolerance.org/member-portal-studies/study-153 https://www.immunetolerance.org/member-portal-studies/study-154 https://www.immunetolerance.org/member-portal-studies/study-155 https://www.immunetolerance.org/member-portal-studies/study-156 https://www.immunetolerance.org/member-portal-studies/study-16 https://www.immunetolerance.org/member-portal-studies/study-17 https://www.immunetolerance.org/member-portal-studies/study-18 https://www.immunetolerance.org/member-portal-studies/study-19 https://www.immunetolerance.org/member-portal-studies/study-2 https://www.immunetolerance.org/member-portal-studies/study-20 https://www.immunetolerance.org/member-portal-studies/study-21 https://www.immunetolerance.org/member-portal-studies/study-22 https://www.immunetolerance.org/member-portal-studies/study-23 https://www.immunetolerance.org/member-portal-studies/study-24 https://www.immunetolerance.org/member-portal-studies/study-25 https://www.immunetolerance.org/member-portal-studies/study-26 https://www.immunetolerance.org/member-portal-studies/study-27 https://www.immunetolerance.org/member-portal-studies/study-28 https://www.immunetolerance.org/member-portal-studies/study-29 https://www.immunetolerance.org/member-portal-studies/study-3 https://www.immunetolerance.org/member-portal-studies/study-30 https://www.immunetolerance.org/member-portal-studies/study-31 https://www.immunetolerance.org/member-portal-studies/study-32 https://www.immunetolerance.org/member-portal-studies/study-33 https://www.immunetolerance.org/member-portal-studies/study-34 https://www.immunetolerance.org/member-portal-studies/study-3478 https://www.immunetolerance.org/member-portal-studies/study-3479 https://www.immunetolerance.org/member-portal-studies/study-3481 https://www.immunetolerance.org/member-portal-studies/study-3482 https://www.immunetolerance.org/member-portal-studies/study-3483 https://www.immunetolerance.org/member-portal-studies/study-3484 https://www.immunetolerance.org/member-portal-studies/study-3485 https://www.immunetolerance.org/member-portal-studies/study-3486 https://www.immunetolerance.org/member-portal-studies/study-3487 https://www.immunetolerance.org/member-portal-studies/study-3488 https://www.immunetolerance.org/member-portal-studies/study-3489 https://www.immunetolerance.org/member-portal-studies/study-3490 https://www.immunetolerance.org/member-portal-studies/study-3491 https://www.immunetolerance.org/member-portal-studies/study-3492 https://www.immunetolerance.org/member-portal-studies/study-3493 https://www.immunetolerance.org/member-portal-studies/study-3494 https://www.immunetolerance.org/member-portal-studies/study-3495 https://www.immunetolerance.org/member-portal-studies/study-3496 https://www.immunetolerance.org/member-portal-studies/study-3497 https://www.immunetolerance.org/member-portal-studies/study-3499 https://www.immunetolerance.org/member-portal-studies/study-35 https://www.immunetolerance.org/member-portal-studies/study-3500 https://www.immunetolerance.org/member-portal-studies/study-3503 https://www.immunetolerance.org/member-portal-studies/study-3504 https://www.immunetolerance.org/member-portal-studies/study-3505 https://www.immunetolerance.org/member-portal-studies/study-3507 https://www.immunetolerance.org/member-portal-studies/study-3508 https://www.immunetolerance.org/member-portal-studies/study-3509 https://www.immunetolerance.org/member-portal-studies/study-3510 https://www.immunetolerance.org/member-portal-studies/study-3512 https://www.immunetolerance.org/member-portal-studies/study-3513 https://www.immunetolerance.org/member-portal-studies/study-3514 https://www.immunetolerance.org/member-portal-studies/study-36 https://www.immunetolerance.org/member-portal-studies/study-37 https://www.immunetolerance.org/member-portal-studies/study-38 https://www.immunetolerance.org/member-portal-studies/study-39 https://www.immunetolerance.org/member-portal-studies/study-4 https://www.immunetolerance.org/member-portal-studies/study-40 https://www.immunetolerance.org/member-portal-studies/study-41 https://www.immunetolerance.org/member-portal-studies/study-42 https://www.immunetolerance.org/member-portal-studies/study-43 https://www.immunetolerance.org/member-portal-studies/study-44 https://www.immunetolerance.org/member-portal-studies/study-45 https://www.immunetolerance.org/member-portal-studies/study-46 https://www.immunetolerance.org/member-portal-studies/study-47 https://www.immunetolerance.org/member-portal-studies/study-48 https://www.immunetolerance.org/member-portal-studies/study-49 https://www.immunetolerance.org/member-portal-studies/study-5 https://www.immunetolerance.org/member-portal-studies/study-50 https://www.immunetolerance.org/member-portal-studies/study-51 https://www.immunetolerance.org/member-portal-studies/study-52 https://www.immunetolerance.org/member-portal-studies/study-53 https://www.immunetolerance.org/member-portal-studies/study-54 https://www.immunetolerance.org/member-portal-studies/study-55 https://www.immunetolerance.org/member-portal-studies/study-56 https://www.immunetolerance.org/member-portal-studies/study-57 https://www.immunetolerance.org/member-portal-studies/study-58 https://www.immunetolerance.org/member-portal-studies/study-59 https://www.immunetolerance.org/member-portal-studies/study-6 https://www.immunetolerance.org/member-portal-studies/study-60 https://www.immunetolerance.org/member-portal-studies/study-61 https://www.immunetolerance.org/member-portal-studies/study-62 https://www.immunetolerance.org/member-portal-studies/study-63 https://www.immunetolerance.org/member-portal-studies/study-64 https://www.immunetolerance.org/member-portal-studies/study-65 https://www.immunetolerance.org/member-portal-studies/study-66 https://www.immunetolerance.org/member-portal-studies/study-67 https://www.immunetolerance.org/member-portal-studies/study-68 https://www.immunetolerance.org/member-portal-studies/study-69 https://www.immunetolerance.org/member-portal-studies/study-7 https://www.immunetolerance.org/member-portal-studies/study-70 https://www.immunetolerance.org/member-portal-studies/study-71 https://www.immunetolerance.org/member-portal-studies/study-72 https://www.immunetolerance.org/member-portal-studies/study-73 https://www.immunetolerance.org/member-portal-studies/study-74 https://www.immunetolerance.org/member-portal-studies/study-75 https://www.immunetolerance.org/member-portal-studies/study-76 https://www.immunetolerance.org/member-portal-studies/study-77 https://www.immunetolerance.org/member-portal-studies/study-78 https://www.immunetolerance.org/member-portal-studies/study-79 https://www.immunetolerance.org/member-portal-studies/study-8 https://www.immunetolerance.org/member-portal-studies/study-80 https://www.immunetolerance.org/member-portal-studies/study-81 https://www.immunetolerance.org/member-portal-studies/study-82 https://www.immunetolerance.org/member-portal-studies/study-83 https://www.immunetolerance.org/member-portal-studies/study-84 https://www.immunetolerance.org/member-portal-studies/study-85 https://www.immunetolerance.org/member-portal-studies/study-86 https://www.immunetolerance.org/member-portal-studies/study-87 https://www.immunetolerance.org/member-portal-studies/study-88 https://www.immunetolerance.org/member-portal-studies/study-89 https://www.immunetolerance.org/member-portal-studies/study-9 https://www.immunetolerance.org/member-portal-studies/study-90 https://www.immunetolerance.org/member-portal-studies/study-91 https://www.immunetolerance.org/member-portal-studies/study-92 https://www.immunetolerance.org/member-portal-studies/study-93 https://www.immunetolerance.org/member-portal-studies/study-94 https://www.immunetolerance.org/member-portal-studies/study-95 https://www.immunetolerance.org/member-portal-studies/study-96 https://www.immunetolerance.org/member-portal-studies/study-97 https://www.immunetolerance.org/member-portal-studies/study-99 https://www.immunetolerance.org/members-portal-videos/jen-searle-patient-1-fom-the-mixed-chimerism-study https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---10-years-of-tolerance https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---introductory-address https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---islets---innovation---impact https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---itn-the-next-10-years https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---keynote-address https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---moving-from-mouse-to-man-for-treatment-of-type-1-diabetes https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---oral-tolerance-induction-to-prevent-peanut-allergy https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---spontaneous-operational-tolerance-after-pediatric-liver-transplantation https://www.immunetolerance.org/members-portal-videos/ten-year-symposium---tolerance-in-anca-associated-vasculitis https://www.immunetolerance.org/leadership/leadership-31368 https://www.immunetolerance.org/leadership/leadership-31574 https://www.immunetolerance.org/leadership/leadership-31596 https://www.immunetolerance.org/leadership/leadership-31649 https://www.immunetolerance.org/leadership/leadership-32458 https://www.immunetolerance.org/leadership/leadership-32754 https://www.immunetolerance.org/leadership/leadership-32758 https://www.immunetolerance.org/leadership/leadership-33043 https://www.immunetolerance.org/leadership/leadership-33081 https://www.immunetolerance.org/leadership/leadership-33227 https://www.immunetolerance.org/leadership/leadership-33236 https://www.immunetolerance.org/leadership/leadership-33248 https://www.immunetolerance.org/leadership/leadership-33292 https://www.immunetolerance.org/leadership/leadership-34659 https://www.immunetolerance.org/leadership/leadership-35630 https://www.immunetolerance.org/leadership/leadership-35632 https://www.immunetolerance.org/leadership/leadership-35637 https://www.immunetolerance.org/leadership/leadership-35641 https://www.immunetolerance.org/leadership/leadership-35643 https://www.immunetolerance.org/leadership/leadership-35650 https://www.immunetolerance.org/leadership/leadership-35654 https://www.immunetolerance.org/leadership/leadership-35655 https://www.immunetolerance.org/leadership/leadership-35668 https://www.immunetolerance.org/leadership/leadership-35675 https://www.immunetolerance.org/leadership/leadership-35683 https://www.immunetolerance.org/leadership/leadership-35691 https://www.immunetolerance.org/leadership/leadership-35694 https://www.immunetolerance.org/leadership/leadership-35695 https://www.immunetolerance.org/leadership/leadership-35698 https://www.immunetolerance.org/leadership/leadership-35712 https://www.immunetolerance.org/leadership/leadership-35714 https://www.immunetolerance.org/leadership/leadership-35722 https://www.immunetolerance.org/leadership/leadership-35724 https://www.immunetolerance.org/leadership/leadership-35727 https://www.immunetolerance.org/leadership/leadership-36402 https://www.immunetolerance.org/leadership/leadership-36540 https://www.immunetolerance.org/leadership/leadership-36544 https://www.immunetolerance.org/leadership/leadership-36546 https://www.immunetolerance.org/leadership/leadership-36548 https://www.immunetolerance.org/leadership/leadership-36565 https://www.immunetolerance.org/leadership/leadership-36566 https://www.immunetolerance.org/leadership/leadership-36568 https://www.immunetolerance.org/leadership/leadership-36572 https://www.immunetolerance.org/leadership/leadership-36626 https://www.immunetolerance.org/leadership/leadership-36763 https://www.immunetolerance.org/leadership/leadership-36766 https://www.immunetolerance.org/leadership/leadership-36904 https://www.immunetolerance.org/leadership/leadership-36921